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Approximately 11,000 people are diagnosed with skin cancer in Ireland every year 
and approximately 1,000 of these present with malignant melanoma. Due to lifestyle 
changes and an increase in UV exposure, incidences are expected to continue to rise 
despite the presence of health campaigns.  
Immune cells, called macrophages, have been documented to represent up to 50% of 
the tumour mass in some melanomas. However, we have only a nascent understanding 
of the role of these cells in tumour biology and treatment responses. One treatment 
offered to advanced melanoma patients is electrochemotherapy, which has 
exceptionally high complete local response rates of up to 80%, and is under 
investigation with the replacement of chemotherapy with non-cytotoxic drugs such as 
calcium. Calcium electroporation has shown the ability to induce comparable response 
rates and is under increased scrutiny due to the presence of a case report in which a 
systemic anti-melanoma response was seen following treatment. 
While the effect of electroporation, and increasingly, calcium electroporation on 
tumour cells has been well documented. The effect of these treatments on bystander 
cells in the treatment area, such as tumour-associated macrophages, has not been 
investigated. 
Here we present clinical findings of the presence of distinct macrophage populations 
recruited to melanoma tissue. Using their inflammatory phenotype, effect on gene 
expression within the tumour, and correlation with survival outcomes we give 
compelling evidence that melanomas contain distinct populations of both active, and 
relatively inactive macrophages, which can vary depending on the pathological 
features of the tumour, such as Breslow depth and BRAF mutational status. 
Given the presence of an inflammatory population of macrophages in the tumour, we 
sought to develop an in vitro model in which we could examine the effect of 
electroporation on melanoma conditioned macrophages. Using an adapted model of 
bone marrow-derived monocyte development followed by melanoma conditioning, 
we were able to generate an immunologically active model of melanoma conditioned 
monocytes, which upregulated M2-associated surface receptors, similar to the 
predominant population of intratumoural macrophages. These conditioned cells 
showed no major increase in inducible nitric oxide synthase or arginase expression, as 
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was seen clinically, but were able to affect T cell proliferation and polarization, 
indicating an influential immunological phenotype. 
In chapter 5, we investigate the effect of electroporation on these cells, and show that, 
similarly to tumour cells, their membranes do become reversibly electroporated. Using 
the parameters investigated in chapter 4 we show that calcium electroporation does 
impact their phenotype and functionality, and critically, influences their ability to 
subsequently activate and polarize T cells. Our data indicate that electroporation does 
not deplete intratumoural macrophages or inhibit their ability to drive cytotoxic T cell 
responses, suggesting that, from a macrophage perspective, calcium electroporation 
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Literature Review and introduction 
Sections from this chapter have been published as; 
Tremble LF, Forde PF (2017) Clinical evaluation of macrophages in cancer: role in 














The focus of immunotherapeutics has been placed firmly on anti-tumour T cell 
responses. Significant progress has been made in the treatment of both local and 
systemic malignancies, but low response rates and rising toxicities are limiting this 
approach. Advancements in the understanding of tumour immunology are opening up 
a new range of therapeutic targets, including immunosuppressive factors in the tumour 
microenvironment.  Macrophages are a heterogeneous group of cells that have roles 
in innate and adaptive immunity and tissue repair, but become co-opted by tumours to 
support tumour growth, survival, metastasis and immunosuppression. Macrophages 
also support tumour resistance to conventional therapy. In preclinical models, 
interference with macrophage migration, macrophage depletion and macrophage re-
education have all been shown to reduce tumour growth and support anti-tumour 
immune responses. Here we discuss the role of macrophages in prognosis and 
sensitivity to therapy, while examining the significant progress which has been made 















1.2.1 Historical context 
The potential of utilizing the host immune system to eradicate cancers has been hotly 
debated over the course of the last century. Many doubted the ability to prime the host 
immune system to a tumour which has already successfully evaded detection and 
generated a profoundly immunosuppressive tumour microenvironment (TME). Over 
the last two decades a range of immunotherapies have made it to the clinic, clearly 
proving the point of principle, but the ability of immunotherapy to target more 
aggressive and less immunogenic tumours is still in doubt [1].  
In order to comprehend the limitations of current T cell immunotherapeutics, namely 
T cell checkpoint inhibitors (CPIs), which skew the balance of stimulatory and 
inhibitory signals, it can be useful to imagine the tumours as exerting an 
immunosuppressive force, and the immune system as having a finite immune potential 
(Figure 1.1). Immunosuppression will rise with cancer progression and possibly 
plateau, but at a level both beyond the limit of the normal immune potential and even 
further from the immune potential of an immunocompromised cancer patient, thus 
even with a plentiful supply of neoantigens the immune system is rendered ineffective 
[2,3]. CPIs function to boost the immune potential of the host to a point at which it 
can feasibly compete and overcome the immunosuppression generated by the tumour 
[4,5]. While this is desirable in an anti-cancer context, the effect of such an untethered 
immune response in the host can have serious deleterious effects beyond the tumour 
[6,7]. 
The major successes in immunotherapies for cancer patients have relied upon the 
direct modulation of T cell activation, either by targeting T cell costimulatory proteins 
such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed cell 
death protein 1 (PD-1), or by adoptive T cell transfer using ex-vivo T cell activation 
[8-10]. However, the side effects associated with these drugs appear to be dose 
dependant, cumulative with previous cycles of therapy and additive with other similar 
regimes [11-13]. This apparent limit has led to a shift in research to identify suitable 
complimentary therapies that kill tumour cells in a way which primes the TME for T 




Figure 1.1 Magnitude of immune potential versus tumour generated immunosuppression 
Diagrammatic hypothesis representing immunosuppression over time during cancer progression 
graphed with immune potential. Immune potential is the ability of the immune system to mount an 
effective adaptive immune response. 
Developments in the field of immunology, and the elucidation of the myriad of 
components interacting in the TME, are leading to the development of a new range of 
immunotherapeutics that focus on an expanding set of targets with therapeutic and 
diagnostic potential [16,17]. 
In contrast to many approved immunotherapeutics that boost the immune potential, 
one interest has been in trying to actively reverse the immunosuppression generated 
by the tumour by disrupting immunosuppressive factors in the TME or by disrupting 
cells normally co-opted by tumours [18]. 
One specific vein of research has focused on a subset of the myeloid cell compartment 
comprising the monocyte-macrophage lineage which can be subverted and recruited 
to the tumour as tumour associated macrophages (TAMs). While TAMs can comprise 
up to 50% of the tumour mass, they have been less intensively studied than other 
immune subsets [19]. There is a growing body of literature showing their prognostic 
value, and they are emerging as promising therapeutic targets in oncology [20]. 
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1.2.2 Synopsis of macrophage origin and classification  
TAMs are predominantly derived from circulating populations of monocytes [21]. As 
a simplified paradigm, macrophages have been categorized as classically activated M1 
(inflammatory) which are anti-tumour, or alternatively activated M2 (wound repair) 
which are pro-tumour [22]. The M1 M2 dichotomy was developed by in vitro 
observations but recent advances have led to a more complex spectrum of activation 
states. Both monocyte and macrophage populations frequently display hybrid M1/M2 
phenotypes, or phenotypes that cannot be adequately defined using the M1:M2 system 
[23]. It has been identified that the M1/M2 system is leading to confusion and 
inconsistency between researchers and ultimately impeding progress [24]. 
Others advocate the use of in vivo function to classify M1 M2 macrophages, focusing 
on the inducible nitric oxide synthase (iNOS) (M1): arginase (M2) ratio. With cells 
being defined as inhibitors of cell growth and killers or as promoters of cell 
proliferation and wound repair (Figure 1.2) [25]. Flow cytometry has however led to 
the distinction of a range of macrophage and monocyte types based on their relative 
expression of various cell surface markers [26]. 
From a clinical perspective, the study of macrophages faces a unique challenge, in that 
we find it more amenable to study discretely defined subsets of cells, but it is becoming 
increasingly evident that this is not possible with such a heterogeneous set of cells. 
While many continue to report based on two distinct subtypes, it is important to 
remember that the activation states of macrophages incorporate discrete populations 




Figure 1.2 Synopsis of M1:M2 macrophage dichotomy  
Cluster of differentiation (CD) 11b monocytes (MO) can mature with a heterogeneity of phenotypes 
which together represent a spectrum with M1 and M2 macrophages representing the two extremes of 
that spectrum. In vitro, Interferon γ (IFNγ), Lipopolysaccharide (LPS) and Tumour necrosis factor α 
(TNFα) drive M1 polarization whereas Interleukin 4 (IL-4), Interleukin 10 (IL-10) and interleukin 13 
(IL-13) drive M2 polarization. M1 macrophages express CD68, CD11b, CD38, CD16/32, major 
histocompatibility complex class II (MHC II) and CD80/86, their primary function is dependent on the 
expression and function of inducible nitric oxide synthase (iNOS) which results in the extracellular 
accumulation of nitric oxide (NO) and citrulline which, along with other cytokines, can drive cytotoxic 
anti-tumour T helper 1 (Th1) responses. M2 macrophages express CD68, CD11b, CD163, CD206, 
Galectin 3 and Early Growth Response Protein 2 (Egr2), their primary function is dependent on the 
expression and function of arginase which results in the extracellular depletion of arginine and the 
accumulation of ornithine and urea which are key to wound repair mechanisms but can also promote 





1.2.3 Contribution to tumourigenicity 
Macrophages have been implicated in all aspects of tumour growth and spread, but 
they are also known to be critical mobilizers of the adaptive immune system (Figure 
1.3) [28]. As such they play an enigmatic role in tumour development and the 
generation of anti-tumour responses.  
In line with their roles in immune stimulation and antigen presentation, there is 
evidence high macrophage infiltration in the early stages of tumour growth can result 
in tumour destruction while low levels of infiltration support tumour growth [29,30]. 
Macrophages can promote anti-tumour responses but advanced tumours have been 
shown to polarize TAMs into an M2-like phenotype [31].  
Tumours can secrete a range of chemoattractants that promote recruitment of 
monocyte and macrophage populations [32]. TAMs become co-opted to promote 
tumour cell proliferation and survival, tumour vascularization and 
immunosuppression along with supporting extravasation and growth of tumour cells 
at distal sites [33].  
The importance of TAMs is evident across the literature, they can affect patient 
prognosis and determine sensitivity to a range of therapies. Preclinical studies and 




Figure 1.3 Synopsis of pro- and anti-tumoural effects exerted by macrophages 
Key enzymes and cytokines produced by M1 and M2 macrophages that have the effect of driving or 
inhibiting cancer progression. M1 cells can drive inflammation and cytotoxic Th1 responses while M2 
cells can produce factors such as vascular endothelial growth factor (VEGF) and Prostaglandin E2 
(PGE2), and are involved in the depletion of activated T cells, recruitment of regulatory T cells, tissue 









1.3 Prognostic relevance of macrophages 
1.3.1 Circulating and infiltrating macrophages 
A high density of macrophage infiltration into the tumour has been cited as a negative 
prognostic indicator in a range of solid and haematological malignancies (Tables 1.1-
1.2). Colorectal cancer displays a contrasting trend whereby high macrophage 
infiltration can result in increased patient survival [35-37]. 
Arguably the most robust prognostic evidence is available for breast cancer and 
Hodgkin’s lymphoma. A distinct gene signature in breast cancer has shown high 
macrophage density is prognostic if combined with a high CD4+ helper T cells to 
cytotoxic T cell ratio. The signature closely correlated to the development of 
secondary tumours that could accurately predict survival in women after complete 
resection [38]. A macrophage gene signature has been developed for Hodgkin’s 
lymphoma that can accurately predict survival and response to therapy, indicating that 















Table 1.1 The effect of macrophage infiltration and macrophage related biomarkers on 
prognosis in solid tumours 
Tumour Indicator Prognostic Significance Reference 




High TAM infiltration 
High TAM density 
High CD68+ TAM 
density 
High CD204+ TAM 
infiltration 
High grade, low estrogen 
receptor and 
progesterone receptor 

















Myxoid liposarcoma High  CD68+ TAM 
infiltration 
Shorter OS [45] 
Cervical High CD68+ TAM 
infiltration 
 
High CCL2 expression 
and CD68+ TAM 
infiltration 
Disease progression and 
high grade lesions 
Lower relapse-free 
survival, lower OS, 
increased local and 
distant recurrence, 
vascular invasion, and 




Uveal Melanoma Both High CD68+ and 
CD68+CD163+ TAM 
infiltration 
Shorter OS [48] 
Bladder High CD68+ TAM 
infiltration 
Late clinical staging [43] (M) 
Oral High CD68+ TAM 
infiltration 
Shorter OS [43] (M) 
Thyroid High CD68+ TAM 
infiltration 
Shorter OS [43] (M) 
Ovarian High CD68+ infiltration 
High CD68+ density 
High CD68+CD163+ 
TAM infiltration 




Early clinical staging 












Serum soluble CD163 
 
*Shorter DFS and OS [52] 
Gastric High CD68+ TAM 
infiltration 







Prostate High CD68+ TAM 
density 
Shorter median OS and 
poor clinical outcome 
[54] 
Glioma High CD163+ CD204+ 
TAM infiltration 
Correlates to histologic 
grade 
[55] 
Lung M1:M2 gene signature Increased OS [56] 
NSCLC High CD68+ HLA-DR+ 
(M1) TAM infiltration to 
stroma and islets 










Colorectal High CD68+ TAM 
infiltration 
High CD16+ TAM 
infiltration 
High CD68+ TAM 






Increased OS and 






Clinical data linking macrophage infiltration and prevalence, via macrophage markers, with prognostic 
outcomes in patients with solid tumours. CD68, Colony-stimulating factor 1 (CSF1) and CD16 are 
markers used to identify macrophages, Human leukocyte antigen – DR isotype (HLA-DR) is used to 
identify M1-like macrophages. CD163 is a strong M2 marker while, CD204 and CD206 are markers 
also preferentially expressed by M2-like macrophages. Shaded in gray are indications where high M2-
like macrophage numbers correspond to a positive prognosis. M denotes meta-study. Overall survival 
(OS), 5-year survival (5YS), Disease-free survival (DFS) non-small cell lung cancer (NSCLC), Tumour 








Table 1.2 The effect of macrophage infiltration and macrophage related biomarkers on 











High CD163: CD68 
ratio in the TME 
Shorter OS [59] 
Hodgkin’s lymphoma TAM gene signature, 
High CD68+ cells in 
lymph nodes 
 
High CD68+ CD163+ 
infiltration 
Shorter PFS, increased 
risk of relapse after 
haematopoietic stem 
cell transplant 







Follicular lymphoma High CD68+ 
infiltration 
Shorter OS [62] 
Clinical data linking macrophage infiltration and prevalence, via macrophage markers, with prognostic 
outcomes in patients with haematological malignancies. CD68 is a marker used to identify all 
macrophages, CD163 is used to identify M2-like macrophages. Overall survival (OS), progression free 
survival (PFS), Tumour-associated macrophage (TAM), Tumour microenvironment (TME). 
1.3.2 Histologic localization of macrophages 
Histological examination of colorectal cancer, for which TAM infiltration is a positive 
prognostic indicator, revealed infiltration at the tumour front in colon cancer leads to 
enhanced survival and reduced liver metastasis, irrespective of cluster of 
differentiation (CD) 8+ T cell infiltration [49,63,36,37]. The proximity of the TME to 
the intestinal microbiome has been hypothesized as a potential explanation for the 
differential behaviour of macrophages in colorectal cancer [64]. It is possible that the 
continuous supply of pathogen-associated molecular patterns (PAMPs) available to 
macrophages may outweigh the ability of the tumour to polarize the cells to an M2-
like phenotype. This hypothesis may also explain why similar results have been seen 
in gastric cancer, in which tumours may have varying access to the intestinal 
microbiome depending on the localization of the tumour. Thus, high infiltration of 
macrophages in the tumour nests in gastric cancer is associated with enhanced antigen 




The histological localization of macrophages in breast cancer has shown no correlation 
with prognosis, while in endometrial cancer high TAM infiltration into the tumour 
hotspot (tumour core of necrotic cells) is associated with advanced clinical staging, 
myometrial invasion and histological differentiation [65,66,41]. Characterization in 
other tumour types is warranted. 
1.3.3 Macrophage polarization 
It is possible the results of many studies were adversely affected by failure to 
distinguish pro- and anti-tumour populations. When differentiated in non-small cell 
lung cancer (NSCLC), it was found that high M1-like macrophage infiltration was 
associated with prolonged survival, while the level of M2-like infiltration had no 
impact on survival [56,57]. This is in contrast to an earlier meta study examining the 
prognostic relevance of overall CD68+ infiltration in NSCLC that found no link with 
overall survival (OS) [67].  
Similarly, in patients with hepatocellular carcinoma after curative resection, high 
numbers of CD11c+ dendritic cells and low numbers of CD206+ macrophages 
correlated with extended OS, whereas CD68+ TAM infiltration displayed no 
prognostic significance [68]. In ovarian cancer there is inconsistent evidence on the 
prognostic effect of CD68+ cell infiltration, however differentiation of the populations 
revealed that a high M1-like:M2-like ratio is prognostically favorable [51,50,69,70]. 
Together these data indicate whole macrophage counts used to explore the prognostic 
effects in other cancers may not accurately reflect the true trend or scale of the effect 
imposed by pro-tumourigenic macrophage populations. The ability to draw robust 







1.4 Role of macrophages in therapeutic response 
1.4.1 Chemotherapy 
1.4.1.1 Effect of chemotherapy on macrophages 
Conventional chemotherapies are considered immunosuppressive due to toxic 
systemic effects on rapidly proliferating leukocytes and bone marrow progenitors 
resulting in leukocyte depletion [71]. Chemotherapy has also been shown to stimulate 
the secretion of colony stimulating factor 1 (CSF1) by tumour cells, which is a potent 
chemoattractant for macrophages, and results in an accumulation of TAMs in the TME 
which contribute to chemoresistance [72].  
1.4.1.2 Prognostic significance of macrophages in response to chemotherapy 
High levels of infiltrating CD68+ and CD163+ cells are a negative prognostic marker 
for patients with oesophageal cancer undergoing preoperative neoadjuvant 
chemotherapy and indicates patients are less likely to respond to chemotherapy [73]. 
The CD8: CD68 cell ratio is a predictive biomarker for response to neoadjuvant 
chemotherapy in breast cancer patients [74,38].  These effects were found to be at least 
in part due to the upregulation of CSF1 by tumour cells in response to chemotherapy. 
A high density of CD163+ cells at the invasive front in oral squamous cell carcinoma 
was found to correlate to a poorer outcome after surgery following 5- Fluorouracil (5-
FU) based chemoradiotherapy [75]. 
On examination of the histologic localization of macrophages, CD68+ in the 
parenchyma negatively correlated to lymphatic metastasis after neoadjuvant 
chemotherapy, in contrast to the number in the dense fibrous stroma which directly 
correlated to the number of positive lymph nodes, indicating the role of macrophages 
depends on intratumoural localization in breast cancer [74]. 
1.4.1.3 The role of macrophages in chemoresistance 
Macrophages are central coordinators of immune responses during chemotherapy 
[76]. Blockade of macrophage recruitment increased the efficacy of paclitaxel in 
breast cancer, resulting in diminished growth of both primary and metastatic tumours 
[38]. Suppression of CD8+ effector T cells by the production of Interleukin 10 (IL-10) 
has been shown to reduce anti-cancer cytotoxicity [77]. IL-10 production by 
macrophages also limits the efficacy of chemotherapy in breast cancer and was 
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subsequently shown to indirectly enhance tumour growth by down regulating 
Interleukin 12 (IL-12) production by dendritic cells (DCs) which is required for 
cytotoxic CD8+ T cell responses [76].  
Macrophages are critical mediators of wound and tissue repair and it is possible that 
these functions can be naturally adapted by the tumour to generate chemotherapeutic 
resistance [78]. M2-like macrophages derived from human acute monocytic leukemia 
(THP-1) cells, were shown to reduce apoptosis in addition to enhancing tissue repair 
and angiogenesis in response to etoposide, a topoisomerase inhibitor [79,80]. 
Both macrophage depletion and re-education to an M1 state have been shown to 
increase the efficacy of chemotherapy [81-83]. The induction of M1 polarization using 
host-produced histidine-rich glycoprotein to reduce signaling by the M2 driver 
Phosphatidylinositol-glycan biosynthesis class F protein (PIGF) has been shown to 
restore sensitivity to chemotherapy, reduce tumour growth and reduce metastasis, 
indicating that M1 polarization can combat all major aspects of disease [81].  
Macrophage modulating therapies have an advantage over many other 
immunotherapeutics because they can be used to synergistically improve outcome 
with chemotherapy, whereas the results of combining CPIs with chemotherapy have 
shown very little or no effect on OS or quality of life [38]. 
1.4.2 Radiotherapy 
1.4.2.1 Effect of radiotherapy on macrophages 
Conventional fractionated radiotherapy is considered immunosuppressive, as 
radiation primarily leads to apoptotic cell death, but it can also lead to necrotic cell 
death and mitotic catastrophe [84,85]. 
The accumulation of macrophages in the TME after radiotherapy is due to the ability 
of macrophages to survive clinically relevant doses of radiotherapy coupled with an 
influx of monocytes after radiotherapy [86,87]. While this may seem attractive in the 
generation of an abscopal effect, there is much research showing that the influx of 
monocytes and macrophages is responsible for therapy failure due to their role in 
vasculogenesis and angiogenesis [88,89]. 
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1.4.2.2 Role of macrophages in radioresistance 
Murine models of oral and brain cancer have shown macrophages infiltrating the 
tumour after radiotherapy were primarily M2-like and supported vasculogenesis and 
tumour growth [90,91,89,92]. 
Curiously, ionizing radiation skews macrophages from an M2-like to an M1-like 
phenotype, suggesting an enigmatic role of macrophages in radiotherapy [93]. 
Characterization of the TME post irradiation reveals decreased levels of the anti-
inflammatory markers CD163, IL-10, Vascular cell adhesion protein 1 (VCAM-1) and 
CD206 while significantly increasing the inflammatory markers iNOS, CD80, CD86 
and Human Leukocyte Antigen-DR isotype (HLA-DR) [94]. However, irradiated 
macrophages were still able to enhance tumour cell invasion and supported the 
angiogenic process of tumour cells indicating the retention of M2-like traits. Blocking 
macrophage migration into the TME after radiotherapy has been shown to enhance 
responses in murine models [86]. 
1.4.2.3 Prognostic significance of macrophages in response to radiotherapy 
Prognostically, there is limited evidence on the effect of macrophages in patients 
undergoing radiotherapy. Macrophages have been shown to predict response to short 
course pre-operative radiotherapy for colon cancer, with data suggesting a high 
infiltration of M1-like macrophages is likely to result in a reduced response, no effect 
was seen by M2-like macrophages [95].  
1.4.3 T cell checkpoint inhibitors 
CPIs have been the most notable achievement in the development of immunotherapy 
for cancer patients, but there has been limited interest in the role of myeloid cells in 
their clinical application to date.  
Macrophages are key coordinators of adaptive immune responses, and express a range 
of T cell costimulatory and co-inhibitory molecules, known as the B7 family [96]. 
Crosstalk between tumour cells and macrophages can regulate the expression of B7 
family molecules on both tumour cells and macrophages [97]. The TME is abundant 
in IL-10 and tumour necrosis factor α (TNF-α), which can both upregulate 
Programmed death-ligand 1 (PD-L1) expression on macrophages, via signal 
transducer and activator of transcription 3 (STAT3) signalling, which is responsible 
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for the inactivation and depletion of activated T cells [98-100]. PD-L1 has been 
implicated as a major signalling molecule associated with immune escape by tumours 
[101].  
In addition to their role in facilitating T cell responses, macrophages are critical 
mediators of many therapeutics that employ antibodies with fully humanized fragment 
crystallisable region (Fc) domains [102]. While the primary function of antibodies is 
the activation or neutralization of their targets, the choice of antibody (Ab) Fc domains 
are known to influence their efficacy [103]. CD16, the receptor for Immunoglobulin 
type G subclass 1 (IgG1) is expressed primarily by macrophages and Natural killer 
(NK) cells and is responsible for the neutralization of antibody targets via antibody-
dependent cellular cytotoxicity (ADCC) or phagocytosis [104,105]. The capacity to 
generate ADCC responses is dependent on two variables. Firstly, the ability of the 
antibody used to bind Fc receptors, and secondly on the activation state of the Fc 
receptor (FcR) expressing cell [106,107]. 
1.4.3.1 Anti-CTLA4 
Ipilimumab is a fully human IgG1 monoclonal antibody (mAb) that interacts with Fc 
γ receptor 3A (FcγRIIIA) (CD16) expressing cells [108,109]. Ipilimumab efficacy 
relies on two mechanisms. Firstly, interference with CTLA4 binding on effector T 
cells, and secondly, FcγRIIIA mediated depletion of regulatory T cells (Tregs) by 
ADCC [110,111].  
In a small study of 29 patients receiving Ipilimumab for the treatment of melanoma, 
responders had a higher number of CD68+CD163+ macrophages in the TME before 
treatment and decreased Treg infiltration after therapy. Responders had the highest 
level of circulating non-classical CD16+CD14low macrophages at baseline [108]. In a 
study of 209 melanoma patients receiving Ipilimumab, low absolute monocyte counts 
and low levels of circulating CD14+HLA-DR−/low Myeloid-derived suppressor cells 
(MDSCs) were significantly associated with improved survival [112]. These studies 
indicate macrophages play an active role in response. 
1.4.3.2 Anti-PD-1/PD-L1 
Both PD-1 and PD-L1 are expressed by macrophages, and as such the effect of these 
neutralizing antibodies may have a depletory effect on macrophage numbers 
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[113,114]. PD-1 is expressed on infiltrating macrophages and lymphocytes of 
melanoma patients responding to anti-PD-1 therapy [115]. Response was primarily 
correlated to the proliferation of intratumoural CD8+ T cells and the role of PD-1+ 
macrophages was not examined. A reduction of the proinflammatory Chemokine (C-
C motif) ligand 3 (CCL3) is associated with prolonged survival in metastatic renal cell 
carcinoma patients receiving Atezolizumab [115,116]. 
Evaluation of immunologic correlates during CPI administration is required to 
improve our understanding of the biology of response and development of resistance. 
Due to the very limited number of patients receiving CPIs, our understanding of the 
















1.5 Macrophage modulation in cancer 
A wide range of efforts have been made to enhance anti-tumour responses by 
modulating the behaviour of macrophages. These can be distinguished into 3 groups: 
1) Skewing of monocyte/macrophage polarization  
2) Inhibition of macrophage migration to the TME  
3) Depletion of monocyte/macrophage populations  
Interest has been shown in a wide range of modulatory mechanisms with varying 
degrees of success. The most promising include granulocyte-macrophage colony-
stimulating factor (GM-CSF), the chemokine (C-C motif) ligand 2 (CCL2)/ C-C 
chemokine receptor type 2 (CCR2) axis and the CSF1/CSF1 receptor (CSF1R) axis. 
 
 
Figure 1.4 Mechanisms of macrophage targeting in cancer 
Tumour associated macrophages are a negative prognostic marker in a range of cancer types and many 
attempts have been made to interfere with macrophage behaviour in the tumour microenvironment. 
Tumour-associated macrophages are readily trafficked to the tumour microenvironment, and are 
thought to have an unactivated or M1-like phenotype. Following recruitment to the tumour 
macrophages are polarized to an M2-like phenotype. Main mechanisms of treatment have focused at 
depleting intratumoural or peripheral macrophages, inhibiting the migration of macrophages to the 






1.5.1 Treatment with GM-CSF 
GM-CSF promotes the expansion of granulocytes and monocytes, polarizes 
macrophages to an M1-like anti-tumour phenotype and can skew cells towards a type 
one phenotype capable of driving anti-tumour Th1 responses [117-121]. GM-CSF has 
been approved for the second line treatment of paediatric high-risk neuroblastoma in 
combination with Interleukin 2 (IL-2) and 13-cis-retinoic acid, and has been 
recommended for the amelioration of febrile neutropenia in solid and haematological 
malignancies by The American Society of Clinical Oncology [122]. 
There is currently a phase 2/3 trial in the recruitment phase examining the 
administration of recombinant GM-CSF, Bacillus Calmette–Guérin (BCG) and 4 
lethally irradiated melanoma cell lines for the treatment of pre-malignant melanoma 
(NCT01729663). 
Sipeleucel-T is a therapeutic vaccine approved for castration-resistant prostate cancer, 
composed of autologous peripheral blood mononuclear cells (PBMCs) cultured ex 
vivo with prostatic acid phosphatase-GM-CSF (PAP-GM-CSF) [123]. Despite gaining 
approval, it only modestly enhanced OS (25.8 vs 21.7 months) with no improvement 
in time to progression [124]. GVAX is a vaccine comprised of a patient’s own cancer 
cells stimulated to secrete GM-CSF and then irradiated to prevent further proliferation 
[125]. GVAX has recently been given breakthrough designation for pancreatic cancer 
in combination with CRS-207, a listeria-based therapeutic vaccine, after positive 
phase 2 results [126]. Interestingly, GVAX has been shown to induce PD-L1 positive 
‘post-immunotherapy lymphoid aggregates’ in murine models of pancreatic 
adenocarcinoma that may prime the tumour into an immunogenic state [127,128]. 
Building on that work the authors performed an early stage clinical trial with GVAX 
and Ipilimumab which showed clinical benefit [129]. These studies were performed 
before the approval of anti-PD-1 antibodies, and it is likely this combination will offer 
enhanced outcomes. A clinical trial is now recruiting (NCT02648282).  
There have been fears surrounding the administration of GM-CSF due to observations 
of constitutive GM-CSF expression by advanced cancers [130]. GM-CSF can induce 
pleiotropic effects depending on its concentration and receptor, including differing 
effects on survival and proliferation [131]. Tumour cells can utilize GM-CSF in an 
autocrine or paracrine mechanism to stimulate growth and proliferation [132,133].  
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1.5.2 Interference with the CCL2/CCR2 axis 
1.5.2.1 Rationale for the modulation of the CCL2/CCR2 axis 
CCR2 is a chemokine receptor present on inflammatory monocytes that it is required 
for mobilization from the bone marrow and recruitment to the TME [134]. Tumours 
can upregulate CCL2 expression, its cognate ligand, from both tumour cells and 
stromal cells resulting in an upregulation of CCR2+ inflammatory monocytes and 
matrix metallopeptidase 9+ (MMP-9) neutrophil infiltration [135-142].  
CCL2 has been shown to increase the survival of PBMCs and clearance of apoptotic 
cells which may be beneficial in an anti-tumour context, however CCL2 also drives 
M2 polarization suggesting it is more likely to play a negative role in cancer patients 
[143,144]. Inhibition of the CCL2/CCR2 pathway has been shown to potently inhibit 
the development of metastasis in murine models of hepatocellular carcinoma, breast 
and prostate cancer [145-148]. Murine models of pancreatic ductal adenocarcinoma 
(PDAC) have shown that CCR2 inhibitors can induce a 3-fold reduction in tumour 
burden [149]. 
Both chemotherapies and radiotherapy have been shown to upregulate CCL2 
production by tumour cells and stromal cells [150,151]. Addition of anti-CCL2 
antibodies is additive with chemotherapy in models of ovarian and prostate cancer, 
and with radiotherapy in models of PDAC [152,153,147,154].  
1.5.2.2 Prognostic significance of CCL2 and CCR2 
CCL2 expression has been linked to cancer progression in hepatocellular carcinoma, 
prostate cancer, colorectal cancer, breast cancer and gastric cancer and has been shown 
to promote the induction of tumour growth, tumour cell migration, neovascularization 
and metastasis [155-159,137,160-166,146,141]. Prognostically, high CCL2 in 
combination with (Vascular endothelial growth factor) VEGF in tumour conditioned 
media has been shown to increase the chance of early relapse in breast cancer [167]. 
High intratumoural CCL2 expression is related to a lower 5-year survival (5YS) in 
gastric cancer [168]. Intratumoural expression of both CCL2 and CCR2 are associated 




1.5.2.3 Clinical modulation of the CCL2/CCR2 axis 
Clinical inhibition of CCL2 initially failed to generate significant effects. Carlumab, 
a monoclonal antibody against CCL2, was found to be safe and tolerable in patients 
but reduction in free CCL2 was short lived and failed to achieve an objective response 
in solid tumours (NCT01204996) [170,171]. MLN1202, a similar antibody, was 
trialled in patients with bone metastasis from solid tumours, and resulted in reduced 
urinary N-telopeptide (uNTX) levels but with minimal therapeutic success [172]. 
Further to the poor therapeutic responses, in murine models a bounce back effect in 
CCL2 levels was observed in which levels quickly returned to baseline or higher than 
pre-treatment levels resulting in accelerated death [173]. 
An orally active CCR2 antagonist PF-04136309, has been shown to reduce growth of 
PDAC and enhance survival. Phase 1b trials with the chemotherapy regime 
FOLFIRINOX (folinic acid, fluorouracil, irinotecan and oxaliplatin) have shown that 
it is safe, tolerable, and enhances survival [174]. Levels of peripheral circulating 
monocytes are inversely related to survival in pancreatic cancer [149]. Systemic CCR2 
inhibition inhibits the mobilization of inflammatory monocytes from the bone marrow, 
consequently lowering monocyte infiltration to the TME. Preclinical models suggest 
the results in PDAC may translate into other tumour types, however the unique TME 
of PDAC, with high innate immune cell infiltration and T cell immune privilege, must 
be considered unique so recapitulation of the results in other tumour types is uncertain 
[175,176].  
CCR2+ macrophages suppress the infiltration of matrix MMP-9+ neutrophils to the 
TME [177]. In murine models of cervical cancer, when macrophages are depleted in 
the TME, protumourigenic neutrophils are recruited. Consequently, no major 
difference in tumour incidence or tumour burden is seen between CCR2 null and wild 
type mice, with only a small delay from dysplasia to carcinoma being noted [178]. It 
is possible that this compensatory influx of neutrophils may be inhibited by the dense 
desmoplastic in pancreatic cancer, indicating the therapeutic benefit of PF-04136309 





1.5.3 Interference with the CSF1/CSF1R axis 
1.5.3.1 Rationale for modulation of the CSF1/CSF1R axis 
CSF1 is a secreted cytokine that binds CSF1R on cells and which can control the 
production, migration, function and differentiation of macrophages [179]. CSF1R is 
predominantly expressed on myeloid cells of the monocyte-macrophage lineage and 
its inhibition has been used in various preclinical models for local 
macrophage/monocyte depletion [180-182]. CSF1R mediated depletion has been 
shown to increase the efficacy of chemotherapy, radiotherapy, angiogenic inhibitors, 
and CPIs [72,183,92,184,185]. In addition to enhancing monocyte migration, CSF1 
binding has been shown to promote the development of M2-like macrophages 
[186,187]. 
Targeting CSF1R has the added advantage of being highly expressed on potently 
immunosuppressive MDSCs and can inhibit the migration of both macrophages and 
monocytic MDSCs to the TME [119, 120]. Along with M2-like macrophages, MDSCs 
secrete high levels of indolamine 2,3-dioxygenase (IDO) and have been implicated in 
resistance to CPIs and rapid outgrowth of B16 cell line tumours [119]. 
Unlike GM-CSF which results in upregulation of PD-L1 expression on immune 
infiltrates, inhibition of CSF1 signalling appears to upregulate CTLA-4 on tumour 
infiltrating CD8+ T cells in addition to enhancing PD-L1 expression on macrophages 
and tumour cells, but with a concomitant decrease in PD-1 expression by monocytes 
and macrophages [185]. Inhibition of signalling by CSF1R on macrophages has been 
shown to enhance antigen presentation and T cell effector functions. Combination with 
CPIs was shown to induce tumour regression in murine models of PDAC [185]. 
While CCL2:CCR2 inhibitors can inhibit the mobilization of monocytes from the bone 
marrow and may result in a build-up of potentially pro-tumour cells elsewhere, anti-
CSF1R antibodies deplete macrophages. There has been evidence that CSF1/CSF1R 
inhibition can increase metastasis in breast cancer via a compensatory increase in 
expression of granulocyte-colony stimulating factor (G-CSF), however this has not 




1.5.3.2 Prognostic significance of CSF1 and CSF1R 
CSF1R overexpression is associated with a negative prognosis in breast cancer 
patients [189]. In murine models, CSF1R overexpression is associated with reduced 
survival in endometrial, hepatocellular and colorectal cancer and targeting of both 
CSF1 and CSF1R have been shown to increase survival [190]. 
1.5.3.3 Clinical modulation of the CSF1/CSF1R axis 
There are a range of anti-CSF1R antibodies currently in clinical trials designed to 
generate ADCC of tumour cells over expressing CSF1R and TAM depletion (Table 
1.3).  
CSF1R is a member of the KIT family of tyrosine kinases. Imatinib Mesylate can act 
as a tyrosine kinase inhibitor to these kinases. A trial using Imatinib in KIT+ patients 
showed clear clinical efficacy with 20/27 achieving stable disease, 1 complete 
response and 4 partial responses. Because of the promiscuity of Imatinib, toxicities 
due to off target effects were significant with 1 in 4 discontinuing treatment due to 
intolerable adverse events (AEs). [191-194]. 
There have been efforts to design tyrosine kinase inhibitors that target CSF1R, but 
they have lacked specificity to CSF1R and induced intolerable side effects unrelated 
to macrophage behavior [195]. A novel compound,  DCC-3014, displays remarkable 
specificity and was due to be used in a First-In-Human trial by the end of 2016 but is 
yet to commence [196]. 
While the efficacy of CSF1R inhibitors has not yet led to their clinical approval, 
effective depletion of TAM numbers has been a positive development which may 








Table 1.3 Clinical trials involving CSF1R inhibitors 
















































































































































































































































































A full list of clinical candidates targeting CSF1R for the prevention of malignancies in registered 
clinical trials. The company, drug format, treatment regimen, stage of clinical trial and clinical trial 






1.5.4 Combinations with T cell checkpoint inhibitors 
Progress has not been aided by a relative under characterization of macrophage 
behaviour during the administration of current immunotherapeutics and analysis of 
how they may impact response. This is more striking when considering the central role 
monocytes and macrophages play in shaping the immune response [200]. There has 
been limited publication of the relationship between response to CPIs and myeloid 
cells, but the level of immunological interrogation of patients focusing on myeloid 
subsets is not clear.  
Ipilimumab (10mg/kg) has been successfully trialed with subcutaneous recombinant 
GM-SCF in metastatic melanoma with an enhanced OS of 17.5 vs 12.7 months, and 
was better tolerated than Ipilimumab alone [201]. The mechanism resulting in reduced 
toxicities is not known, however there was no difference in the objective response rate 
and no significant change in PFS. There is currently a phase 2/3 clinical trial 
examining the combination of Nivolumab and Ipilimumab with or without GM-CSF 
in unresectable melanoma (NCT02339571).  
Positive results of clinical trials examining macrophage modulation will intuitively 
result in future trials combining them with CPIs. Some of these combinational 
approaches are entering early stage clinical trials, but there have also been a number 
of trials which have indirectly combined CPIs with macrophage modulation and seen 
positive results. 
Trabectedin is a drug approved for soft tissue sarcoma that binds the minor groove on 
deoxyribonucleic acid (DNA) resulting in a poorly characterized DNA damage in all 
cells, but critical to its anti-tumour efficacy is its ability to selectively induce apoptosis 
in monocytes and macrophages, reduce recruitment of CD68+ monocytes to the TME 
and reduce CCL2 and Interleukin 8 (IL-8) levels [202-204]. Trabectedin has been 
shown to be synergistic with anti-PD-1 antibodies in murine models of ovarian cancer 
with the generation of systemic anti-tumour immunity [205]. It has been approved for 
the treatment of soft tissue sarcoma under the trade name Yondelis, and is currently in 
clinical trials for use in breast, prostate and paediatric sarcomas. The prolonged period 
of treatment required to see an effect on macrophage populations makes it unlikely to 
exert an observable effect in fast growing or late stage tumours.  
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MGN1703, a DNA-based toll-like receptor (TLR) agonist is being trialled in advanced 
solid malignancies with Ipilimumab (NCT02668770). Similarly, IMO-2125, a 
synthetic TLR-9 agonist which is expressed by plasmacytoid DCs but also to a lesser 
extent by monocytes and macrophages, is being trialled in combination with 
Ipilimumab in patients with metastatic melanoma (NCT02644967). If successful data 
emerges from these trials it will increasingly turn focus towards the role of innate 
immune system in response to CPIs [206].  
Data emerging from the phase 3 clinical trial KEYNOTE-252/ECHO-301 suggests 
that Epacadostat, an IDO inhibitor, in combination with Pembrolizumab can improve 
outcome for stage III/IV unresectable or metastatic melanoma patients. IDO is 
primarily secreted by M2 macrophages but can also be produced directly by tumour 
cells in cancer patients. A phase 3 trial is currently recruiting 600 patients to further 














1.6 Challenges of macrophage modulation 
Side effects associated with CPIs are dose dependant (Table 1.4), it appears they are 
also cumulative to the cycles received and additive with other CPIs [207,11,12,14]. 
The most recent evidence to emerge from CheckMate 067 examining Ipilimumab and 
Nivolumab in advanced melanoma, has suggested the side effects are not cumulative 
but remain high with 58% of patients experiencing grade 3 or 4 AEs. Intuitively this 
has led to a shift in therapeutic design, which has been predominantly focused on 
engineering or stimulating T cells ex vivo. However, it is uncertain if these cells will 
be able to overcome the immunosuppressive environment that acts to ‘turn off’ these 
cells after readministration. 
Table 1.4 Incidence of immune related AEs (irAE) seen in patients receiving Ipilimumab 
 0.3 mg/kg 3 mg/kg 10 mg/kg 
Incidence irAEs 26% 56% 70% 
Incidence grade ¾ 
irAEs 
0% 7% 25% 
Incidence of drug 
discontinuation due 
AEs 
13% 10% 27% 
Numbers taken from [148]. 
The most notable and promising examples of successful macrophage modulation have 
been found in murine models on PDAC and these are now beginning to show efficacy 
in the clinical setting, but the unique composition of the pancreatic cancer TME may 
not accurately reflect the potential of macrophage modulation in other tumour types. 
It is hypothesized that the success seen may be due to the restricted flow of cells into 
and out of the microenvironment resulting in a reduced ability to compensate for a loss 
of macrophage function and consequent tumour inhibition [208]. It however appears 
likely that macrophage modulating therapies will compliment CPIs, and it will be of 
keen interest to see if the reduced AEs seen with GM-CSF and Ipilimumab will be 
seen with other therapies designed to reduce immunosuppressive factors in the TME. 
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While some have been quick to suggest that the ability to understand and direct 
macrophage behaviour represents an immunotherapy breakthrough it is clear from 
recent clinical evaluation that manipulation of macrophages as a stand-alone therapy 
in its current state is insufficient for therapeutic success [209]. However, it appears 
macrophage depletion may be a more effective strategy than macrophage re-education 
due to the profound immunosuppressive force exerted by advanced tumours [210]. 
In addition to the combination of macrophage modulation and immunotherapies, there 
is significant scope and promise for their combination with other therapies. For 
example, the anti-tumour effect of serine/threonine-protein kinase B-Raf (BRAF) 
inhibitors was noted to be reliant on host tumour-directed immune responses [211]. 
50% of advanced melanomas are BRAF positive and initially respond to therapy, but 
tumours develop mechanisms of acquired resistance and become refractory [212]. In 
preliminary studies, inhibiting monocyte and MDSC influx to the TME synergistically 
enhanced the effect of BRAF inhibition [213,214]. There is mounting preclinical 
evidence to justify the use of macrophage modulating therapies with BRAF inhibitors 
in advanced melanoma. 
Preclinical data in murine models has shown that the effect of immunotherapy in 
mouse models is more effective in the early stages of disease progression, which is 
generally defined by a low concentration of immunosuppressive elements in the TME 
[215-217]. While the reversal of this immunosuppression may restore sensitivity, 
delineation of the primary immunosuppressive factors responsible for the reduction in 
efficacy is difficult due to the plethora of interacting factors and systems in the TME. 
Significant literature is available on many factors, but their relative importance in 
determining sensitivity to therapy has not been fully elucidated. The clinical 
prognostic evidence on immunosuppressive factors in patients undergoing treatment 
is limited, but do suggest that they are key to the development of systemic and durable 
anti-cancer responses [3,218-220].  
The form of cell death induced by existing anti-cancer treatments has been of intense 
interest [221]. Evidence of immunogenic cell death may not only reveal underlying 
mechanisms of response but may leave patients more responsive to combination or 
subsequent treatments which also induce immunostimulatory mechanisms [222]. 
Therapies such as electrochemotherapy (ECT), which involve the local delivery of 
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electrical pulses to tumour tissue, termed electroporation (EP), which are optimised to 
reversibly induce pores in the cell membrane, have been shown to induce an 
immunogenic form of cell death [223]. Using ECT the cells display enhanced uptake 
of chemotherapeutic which can allow a reduced dose of chemotherapy to be 
administered while retaining efficacy [224]. This may give treatment dual roles in 
increasing the immunogenicity of treatment, by supplying an ablative and 
immunogenic form of cell death with the reduction of immunosuppressive 
chemotherapeutics. Furthermore, recent clinical trials have substituted chemotherapy 
for calcium, which can retain the efficacy of treatment and may improve the 
immunogenic capacity of treatment. In line with this hypothesis, a case report has 
shown that an advanced melanoma patient given both calcium EP and ECT underwent 
a systemic and durable anti-cancer response [225]. As these effects have not been seen 
with ECT alone, it is hypothesized that the increased immunogenicity of calcium EP 
is responsible for the response seen. These effects have not been recapitulated in other 
patients treated, but may indicate that treatment is lowering the level of 
immunosuppression within the TME. Understanding the mechanisms involved will 
allow us to understand if macrophages play a role in this response or if macrophage 
targeting therapies can complement these effects. 
Targeting of macrophages has been shown to profoundly shape the immune response 
and we now have a range of sophisticated therapeutics that are beginning to make 
impacts in the clinic. Rational design of immunotherapeutics that will increase their 
efficacy, response rates and generate systemic and durable response rates will require 
a holistic mind-set towards understanding the immune system. Given the central role 
that macrophages play in shaping the immune response they will play an integral role 







1.7 Current outlooks in melanoma 
Cutaneous malignant melanoma is a form of skin cancer which affects approximately 
20 people in every 100,000 per annum in caucasian populations, with a lifetime risk 
of 1 in 70 [226]. While incidence rates are rising globally due increased diagnosis rates 
as a result of screening and awareness, it is believed true incidence rates are also rising 
due to changing lifestyle habits resulting in increased exposure to the sun [227]. 
Incidence rates are higher in men and typically highest in countries in which ultraviolet 
light is highest, such as New Zealand and Australia [226]. Melanoma arises from the 
malignant transformation of pigment-containing cells known as melanocytes, which 
can penetrate into the subcutaneous fat and spread throughout the body. Melanomas 
commonly harbour mutations such as BRAF and Ras mutations but over 200 somatic 
driver mutations have been identified [228]. Many melanomas are frequently reported 
to arise from suspicious nevi, which have recently grown or changed phenotypically 
[229]. These pre-malignant nevi commonly harbour NRAS mutations [230]. 
Localized disease can be effectively treated with a wide local excision. 5-year survival 
for localized disease is over 95%, however for advanced disease survival rates can 
drop as low as 20% [231]. Survival rates for advanced melanoma are currently difficult 
estimate due to a spate of revolutionary drugs which have been approved in the last 8 
years, but 5-year survival rates approaching 40% have been reported in some trials 
[232]. 
New treatments have relied on the discovery of specific BRAF mutations that are 
present in approximately 50% of advanced melanoma and can be effectively targeted 
along with the development of a range of immunotherapies [233]. There remains a 
high number of melanoma patients who fail to respond to therapy and prediction of 
responders from non-responders is currently poorly distinguishable [234]. Recent 
efforts are focused around the identification of novel targets and understanding the 
biology of response, of which require a holistic and comprehensive understanding of 




1.8 Role of macrophages in melanoma 
Melanoma has been characterized as an immunologically “hot” tumour to reflect the 
relatively high level of intratumoural immune cells and ability of tumour antigens to 
drive specific T cell responses [237,238]. The first T cell check point inhibitor to be 
approved, Ipilimumab, was first approved for use in metastatic melanoma, and since 
then other immunotherapies have been licenced for use in melanoma [8,9,239]. These 
therapies rely on the activation of T cell responses, however an oncolytic virus 
encoding GM-CSF was also approved for melanoma, which relies on myeloid cell 
activation to drive T cell responses [240,241]. While there has been much success, the 
factors determining response to these therapies are still poorly understood.  
In patients receiving Ipilimumab, low circulating absolute monocyte counts and 
MDSCs but high levels of circulating non-classical monocytes and high intratumoural 
CD163+ macrophage counts were associated with improved outcome  [108,112]. Pre-
treatment intratumoural PD-1+ and PD-L1+ along with CD8+ T cells are all 
independent indicators of response to PD-1 inhibitors but cannot fully predict 
responders [115]. PD-1 and PD-L1 are expressed on tumour cells but also on tumour 
infiltrating macrophages [114]. In comparison to Ipilimumab which has an IgG1 
subtype, the two anti-PD-1s approved for use in melanoma have Immunoglobulin type 
G subclass 4 (IgG4) design [242]. IgG4 is a poor inducer of effector immune responses 
by Fc binding, thus its main mechanism of action is thought to be the inhibition of 
signalling through the inhibitory receptor PD-1 [107]. PD-1+ macrophages may act as 
a competitive inhibitor of anti-PD-1 inhibitors, but direct ADCC or effector functions 
are less likely to contribute to therapeutic response.  
Melanomas are known to secrete immunosuppressive chemoattractants for 
macrophages such as transforming growth factor β (TGF- β), IL10, VEGFA, and 
VEGFC [243]. Macrophages are absent from some melanomas but have also been 
documented to represent up to 13% of total immune cell infiltrate, or up to 30% of the 
tumour mass in melanoma [244,245]. While much is understood of the role of 
macrophages in tumours, the specific understanding of their role in melanoma is 
poorly understood [246]. There is conflicting evidence on the prognostic significance 
of macrophage infiltration in melanoma [247,42,248-251]. Macrophages and DCs are 
critical linkers of innate and adaptive immunity in melanoma [252]. Macrophages 
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have been implicated in the development of acquired resistance to BRAF inhibitors, 
and other clinical indications have also suggested a physiological role, such as the 
increased response rate following addition of GM-CSF to an autologous melanoma 
vaccine [213,214,253]. In comparison to tumour infiltrating lymphocytes, which have 
been successfully targeted and are independent predictors of survival, the role of 
macrophages in melanoma appears to be more complex [254-256]. Clinical research 
on melanoma is impeded in comparison to other tumour types by low levels of fresh 
tissue availability. Many studies are restricted to metastatic tumour tissue or tissue 
from mucosal, acral cutaneous or uveal melanomas which are larger in size [257]. As 
a result, research on melanoma is predominantly derived from murine or in vitro 
studies. 
Previous studies have shown that lymphocytic distribution and melanoma subtype can 













1.9 Challenges in the study of macrophages 
1.9.1 Discrepancy between murine and human macrophages 
Unlike T cells which display remarkable similarities between murine and human 
subsets, the interspecies variations between myeloid cells are more pronounced [259-
262]. Differences between human monocytes and macrophages and their murine 
counterparts is particularly striking, with differences in cell surface markers, gene 
expression and functional activity [263]. Macrophage polarization of inflammation-
like and wound repair-like phenotypes are conserved among evolutionarily diverse 
species, with relatively modest differences between human and murine cells, however 
these differences are significant when considered in the translation of treatment 
efficacy and must be taken into special account when considering the translation of 
research from murine to human models [264-266]. 
1.9.2 Factors influencing macrophage behaviour 
Macrophage function is determined by a complex network of epigenetic and 
transcriptional regulation. As described in a seminal review by De Nardo and Ruffell 
(2019), 3 distinct factors determine macrophage phenotype and function, including the 
cells developmental origin, its tissue of residence, and the specific environmental 
stimuli [267]. These factors can affect the epigenetic state of an individual macrophage 
and act to determine the nature of response to a specific stimuli [268,269,262,270]. 
Thus two macrophages may respond differently to the same stimuli based on these 
criteria, and populations of macrophages are a heterogeneous group of discrete and 
individual cells. The phenotype of macrophages appear to be highly plastic, even 
among tissue resident macrophages. Macrophages have been shown to rapidly lose 
their specific phenotype following removal from their microenvironment, while both 
monocyte-derived macrophages, and tissue resident macrophages have been shown to 
change their transcriptional profile to match the new tissue specific macrophage 
prolife when transplanted into a distant tissue [271,272]. Specific transcription factors 
have been identified in the differentiation of specific macrophage subsets, such as Sal-
like protein 1 (SALL1) and myocyte-specific enhancer factor 2C (MEF2C) for 
microglia[273]. While these transcription factors contribute to phenotype they are 




In addition to the ontology of macrophages, many stimuli which macrophages are 
exposed to leave a form of immunological memory. The term trained immunity has 
been used to describe the apparent non-specific immunological memory of the innate 
immune system [274]. Specific epigenetic markers have been documented in 
macrophages in response to specific stimuli that prime the cell for future responses 
[275,276]. The concept of trained immunity aligns with our current understanding of 
epigenetics to highlight the importance of cell ontogeny and the sum of previous and 
current stimuli in understanding macrophage behaviour. Studies have indicated that 
trained immunity can be detected in monocytes a year following vaccination with 
BCG [277]. It is currently unclear how the effects can last beyond the lifespan of 
individually affected monocytes and macrophages but is likely to be a reflection of the 
system wide effect of trained immunity on multiple branches of the immune system, 
including the adaptive immune response [278]. 
1.9.3 In vitro models of macrophage study 
There are many models available for in vitro investigation of murine monocytes. 
Numerous cell lines exist, such as RAW 264.7 cells, however while these cells are a 
stable model of macrophage-like cells, they offer limited translational scope [279]. 
More physiologically representative models include the isolation of peritoneal 
macrophages from sacrificed animals or the development of bone marrow-derived 
macrophages from murine bone marrow [280,281]. Peritoneal macrophages are 
preferred for the study of tissue-resident macrophages, while bone-marrow derived 
monocytes (BMDMs) are used to study monocyte derived macrophages [282]. Within 
these systems there is significant heterogeneity in preparation methods and protocols 
which can ultimately affect their responsiveness [283-285]. Additionally in vitro cell 
culture of microglia, a specialized form of macrophage, has been shown to induce 
rapid and extensive down-regulation of microglia-specific genes following resection 
of brain tissue, indicating that all forms of cell culture may inhibit the recapitulation 







1.9.4 The murine melanoma cell line, B16-F10 
There are a limited number of highly cited cell lines representative of melanoma. A375 
and SK-MEL derivatives are there most common human cell lines each with over 1000 
separate Pubmed citations [286,287].  Murine cell lines are represented by the highly 
cited B16 derived cell lines, and the recently developed Yale University Mouse 
Melanoma (YUMM) cell lines, both of which are syngeneic with C57BL6 mice 
[288,289]. The B16 cell lines were initially differentiated into B16F1 to B16F10 
derivatives which varied on their in vivo aggressiveness, with B16F10 the most 
aggressive. The B16F10 cell line was selected based on its ability to colonize the lung 
and it predominantly and quickly colonizes the liver and lung [290,291]. The B16F10 
cell line has a number of potential immunogenic antigens but is poorly immunogenic 
in vivo [292,293]. The cell line is commonly transfected with ovalbumin to encourage 
antigen specific CD8+ T cell responses [294]. In vitro the cells have a doubling time 
of approximately 17hrs and readily secrete cytokines, including TNF‐α, IL‐1β, IL‐6, 
and TGF‐β, and exosomes which have discrete immunological profiles from the 
parenteral cells [295,296]. The B16F10 cell line does not contain any activating BRAF 
mutations, however some groups have modified the cell line to express the V600E 
mutation found in many human cancers [297]. 
1.9.5 Translation of research 
Much of the available literature on macrophages has been developed on the inference 
that in vitro studies can be used to approximate true physiological behaviour. While 
significant progress has been made in the study of immunology based on in vitro 
observations, it is becoming increasingly accepted that such a format has limited 
applicability in the study of macrophages, which is ultimately reflected by the failure 
of all therapeutic interventions targeting macrophages in cancer discussed here 
[24,267]. In order to improve the translational value of macrophage research it is 
necessary to consider the specific research question, and perform research on 
macrophage populations which adequately reflect in vivo subsets, with the aim of 
minimizing potential epigenetic and functional differences between cell populations 
[298]. In this thesis, we present a step wise process for the optimal study of 
macrophages. It is currently unclear if macrophages exert a physiological role in 
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clinical disease and but we hypothesize that macrophages may be play a role in 
promoting T cell responses in melanoma. In chapter 3, we identify the presence and 
physiological activity of TAMs in human disease. In chapter 4, we present a concept 
to bench approach for the rational development of appropriate BMDMs. And in 
chapter 5, we build on this to utilize the in vitro model to study the potential effect of 




1.10 Aims of thesis 
This thesis had three specific aims; 
1. To evaluate the presence and phenotype of macrophages in human melanoma. 
2. To determine the effect of tumour conditioning on circulating monocytes 
3. To determine the effect of calcium electroporation on the immunogenic 






















Chapter 2  
















In this chapter we present an elongated form of the traditional materials and methods 
designed to provide complete description and clarity of all protocols and reagents used.  
To ensure replicability of the presented methods and results, where multiple products 
of a given name are available from a specific supplier, and the specific reagent 
formulation, purity grade, or clone used, had a material impact on the results presented, 
such as in the case of antibodies, we have endeavoured to supply the name, supplier 
and where applicable, the clone of reagents used. 
If following these definitions, there are multiple products which match the given 




















2.1 Ethical approval and ethical standards 
Human studies were performed under ethical licencing from the Central Research 
Ethics Committee (CREC) of the Cork Research Hospital, with approvals ECM 4 (n) 
17/10/17 and ECM 4 (m) 17/10/17. All patient information was anonymized and 
stored securely on encrypted hard drives. 
Animal procedures were approved and licensed by the Animal Experimentation Ethics 
Committee (AEEC) in University College Cork under licence 2012-047 and 
performed according to the Irish Cruelty to Animals Act, 1876. 
Animal husbandry and handling was performed according to the Directive 
2010/63/EU. 61 mice were culled under a euthanasia-only licence, granted by the 
Animal Welfare Board of University College Cork, and was performed according to 
the Directive 2010/63/EU. Immediately following euthanasia, death was confirmed by 
observation of complete cervical dislocation. 
2.2 Patient Cohort 
Primary melanoma tumour blocks were randomly selected from BRAF tested 
tumours, for each tumour, a single block with a large area of both tumour and 
peritumoural tissue was selected. Patients were untreated prior to tumour excision. 
Pathological data and follow up data was obtained from patient charts. Tumour and 
cohort descriptions are provided (Table 2.1). 
2.3 Immunohistochemistry  
Primary melanoma tumours were formalin fixed and paraffin embedded by the 
Department of Pathology, Cork University Hospital. 3-5μm tissue sections were cut 
and mounted on Superfrost PlusTM slides (ThermoScientific). Slides were then dried 
at 37°C overnight. Slides were then kept at 4°C and stained within 1 month. Slides 
were incubated at 37°C overnight or at 60°C for 1hr to dry the slides and to enhance 







Table 2.1 Pathological features of the tumours stained by immunohistochemistry 
 Patient Characteristics  
Characteristic  No. % 
Sex Male 35 (61) 
 Female 22 (39) 
Age Median 64 years  
 Range 18-85 years  
Subtype Superficial spreading 20 (34) 
 Nodular 19 (32) 
 Acral lentiginous 7 (12) 
 Lentigo maligna 6 (10) 
 Desmoplastic 1 (2) 
 Unknown 5 (8) 
Primary location Acral 11 (19) 
 Head and neck 10 (18) 
 Lower limb 15 (26) 
 Upper limb 12 (21) 
 Trunk 9 (26) 
Breslow depth <1mm 5 (8) 
 1.01-2mm 7 (12) 
 2.01-4mm 13 (22) 
 >4.01mm 32 (54) 
Stage pT1a 2 (4) 
 pT1b 3 (5) 
 pT2a 7 (12) 
 pT3a 8 (14) 
 pT3b 4 (7) 
 pT4a 5 (9) 
 pT4b 28 (49) 
Mitotic count Median 6.5mm  
 Average 10.17mm  
 Range 0-51mm  






Ulceration Yes 33 (49) 









 Brisk 3 (5) 
 Variable 2 (4) 
 Unknown 2 (4) 
Random primary melanoma tumours, screened for BRAF mutational status, were selected for analysis 







2.3.1 Manual IHC staining 
Slides were washed in xylene (Ocon Chemicals) 3 times to remove wax and then 
placed in a decreasing alcohol (2-proponol, Merck) gradient of 90%, 90% and 70% in 
double distilled water (ddH20) to rehydrate tissue sections. Slides were left in each 
solution for 2-3 minutes. Slides were then immersed in ddH20 for at least 5min. For 
epitope retrieval, slides were placed in citrate buffer pH6 (1.92g/L anhydrous citric 
acid (Merck) in ddH2O, adjusted to pH6 with HCl (Scharlau)) in a precise temperature 
control (PT) module for 20min at 95°C which was preheated to 65°C. Following 
epitope retrieval the slides were washed in ddH20. Slides were placed in 3% H2O2 
(Merck) in ddH20 for 10min to quench endogenous peroxidase activity. A margin was 
drawn around the tissue with a 5mm hydrophobic pen (Merck). Slides were incubated 
in blocking solution (5% bovine serum albumin (BSA) (Merck) in phosphate buffered 
saline (PBS) (Merck)) for 1hr at room temperature (RT) in a humidified chamber. 
Blocking solution was washed from the slide with PBS and the slides were incubated 
in a 1 in 100 dilution of iNOS monoclonal antibody (Table 2.2) in blocking buffer for 
60min at RT in a humidified chamber. The primary antibody was then washed from 
the slide with PBS and placed in 3 serial PBS washes for 5min each. Slides were then 
incubated at RT in a 1 in 1000 dilution of goat anti-rabbit alkaline phosphatase IgG 
heavy and light chain (H&L) secondary antibody (Abcam, ab97048) in blocking 
buffer for 30min. The secondary antibody was washed from the slide with PBS and 
then placed in 3 serial PBS washes for 5min each.  Slides were covered in Liquid Fast-
Red Substrate Kit (Abcam), briefly 1 drop of 75x Fast Red Chromogen was added to 
3ml Liquid Fast Red Substrate (both supplied in Liquid Fast-Red Substrate Kit) within 
15min of use and mixed well, this solution was then liberally added to cover the slide. 
Slides were incubated for 20-25min at RT in a humidified chamber. Fast red was 
washed from the slide with ddH20 and the slides were left in ddH20 for 5min. Slides 
were covered in Mayer’s Haematoxylin (Merck) for 20-40sec. The slides were washed 
with ddH20. Slides were dipped rapidly in Scott’s Tap Water (Leica Biosystems) 6-10 
times to blue the Mayer’s Haematoxylin. Slides were coverslipped using aqueous 





2.3.2 Automated immunohistochemical staining 
CD68, CD163 and arginase (Arg) staining (Table 2.2) was performed on an automated 
Benchmark Ultra system (Roche) using the UltraView Universal Alkaline 
Phosphatase Red Detection Kit (Roche) with the standard Ultraview protocol. 
Deparaffinization was performed with xylene, rehydration of tissue was performed 
with a decreasing concentration of alcohol. Antigen retrieval was performed in Cell 
Conditioning 1 solution (Ventana Medical Systems, Inc.) for 20min (Arg), 64min 
(CD163) or 20min (CD68), before addition of 1 drop of primary antibody for 60min 
(Arg) or 32min (CD163 and CD68). Slides were treated with the UltraView Universal 
Alkaline Phosphatase Red Detection Kit (Roche), counterstained in Haematoxylin II 
(Roche) for 4min, blued in Bluing Reagent (Roche) for 4min and cover slips were 
manually mounted in aqueous mounting medium (Vectamount). 
All immunohistochemistry (IHC) slides were examined independently by two trained 
pathologists. The areas of highest staining were identified in peritumoural and 
intratumoural regions. Starting from this site, the number of positively stained cells 
were counted in 4 adjacent high powered fields, under a 40x magnification, which was 
equivalent to a total area of 1mm2. The number of positive cells between both 
pathologists was averaged to give a final value. 
Due to a high number of specimens which were negative for CD68+ and iNOS+ cells 
in the tumoural and peritumoural tissue, CD68 and iNOS staining was stratified semi- 
quantitatively as positive (containing 1 or more positive cells) or negatively stained 
(no positive cells).  
 
Table 2.2 Antibodies used for IHC analysis 
Target Clone Supplier Catalogue # 
CD68 Kp-1 Cell Marque 168M 
CD163 MRQ-26 Cell Marque 163M-18 
Arginase N/A Atlas Antibodies HPA003595 
iNOS SP126 Invitrogen MA5-16422 
Primary antibodies were used to stain specific targets in human FFPE primary melanoma tissues. Listed 
are the human specific antibodies used to identify macrophages and macrophage related enzymes, their 
clone, supplier and catalogue code required to source the antibodies used. 
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2.4 Gene expression analysis of human tissues 
5μm serial sections were cut from primary melanoma formalin-fixed paraffin 
embedded (FFPE) blocks, which were previously selected for staining by IHC, and 
mounted on Superfrost PlusTM slides. The tumour margins were marked on a matched 
haematoxylin and eosin stain (H&E) by trained pathologists. HTG EdgeSeq 
technology was used with the oncology biomarker panel to perform gene expression. 
Cell lysis was performed on tumour tissue, as determined by the marked H&E, 
according to the manufacturer’s instructions. All lysis and ribonucleic acid (RNA) 
sequencing was performed by Elda Biotech LTD under licence of HTG Molecular 
Diagnostics, Inc using proprietary protocols. In brief, nuclease protection probes and 
gene specific barcoded probes were added and complexed to lysed tissue by 
polymerase chain reaction (PCR). Individual probes were purified and the subsequent 
pooled library was run on Lumina next generation sequencing (NGS) technology 
[299]. 
24 samples were analysed along with 3 internal controls. 4 samples failed internal 
quality control analysis, as determined by comparison to internal controls and were 
omitted from all analyses. Pearson correlation values between internal controls were 
used to determine the acceptable variance within samples. Tumour and cohort 
descriptions are provided (Table 2.3) Normalized data on 2,550 oncology biomarker 
related genes was obtained from HTG EdgeSeq software and used for subsequent 
analyses.  
Differentially expressed genes between groups were detected using the DESeq2 
algorithm with adjusted p values. Heat maps were clustered using the Ward-Linkage 
method and generated using the Made4 package v.1.58 within the R environment. The 











Table 2.3 Pathological features of the tumours selected for gene expression 
 Patient Characteristics  
Characteristic  No. % 
Sex Male 13 (65) 
 Female 7 (35) 
Age Median 70.5 years  
 Range 26-85 years  
Subtype Superficial spreading 5 (25) 
 Nodular 11 (55) 
 Acral lentiginous 2 (10) 
 Unknown 2 (10) 
Primary location Acral 4 (20) 
 Head and neck 3 (15) 
 Lower limb 5 (25) 
 Upper limb 5 (25) 
 Trunk 3 (15) 
Breslow depth <1mm 0 (0) 
 1.01-2mm 1 (5) 
 2.01-4mm 2 (10) 
 >4.01mm 17 (85) 
Stage pT2a 1 (5) 
 pT3a 3 (15) 
 pT4b 16 (80) 
Mitotic count Median 12mm  
 Average 11.89mm  
 Range 0-30mm  






Ulceration Yes 15 (75) 









 Brisk 3 (15) 
 Unknown 1 (5) 
Random primary melanoma tumours, screened for BRAF mutational status, were selected for analysis 
by immunohistochemistry. 24 of these tumours were selected for gene expression analysis based on 
tumour tissue availability within the FFPE block. 4 failed internal quality control and were omitted 
from analysis. Above cohort descriptives characterizing both the patient and the melanoma of tumours 
which were successfully analysed for gene expression and presented in chapter 3.  
2.5 B16F10 cell line maintenance 
The B16F10 cell line is a highly aggressive murine melanoma cell line which readily 
metastasizes to the lung and liver when grown in vivo. The cell line was purchased 
from and authenticated by the Developmental Therapeutics Program, Division of 
Cancer Treatment and Diagnosis Tumor Repository (United States of America, USA) 
and maintained in Roswell Park Memorial Institute medium 1640 (RPMI-1640) 
(Merck; R8758) supplemented with 10% foetal calf serum (FCS) (Merck) and 
50units/ml penicillin and 50μg/ml streptomycin (P/S) (Merck) [289]. Cell lines were 
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regularly tested for the presence of mycoplasma infection. This solution is referred to 
as complete RPMI (cRPMI). Cells were cultured at 37°C in a humidified chamber 
with 5% CO2.  To wash or pellet the cells, the cells were centrifuged at 200g. Cells 
were grown in tissue culture treated tissue culture flasks (Sarstedt) or tissue culture 
treated 6/12/24 or 96 well plates (Sarstedt). 
To isolate cells the medium was decanted, the flasks/plates were rinsed in PBS and 1 
volume of trypsin-ethylenediaminetetraacetic acid (EDTA) solution (Merck) was 
added to the cells. The cells were incubated at 37°C until the cells had detached (5-
10min). The trypsin-EDTA solution was then quenched with 2 volumes of cRPMI.  
2.6 Cell counting 
A 200μL aliquot of cells were taken and added to 200μl solution A100 (Chemometec) 
and 200μl solution B (Chemometec). The solution was mixed well for 30sec to allow 
complete cell lysis and then added to a NucleoCassetteTM (Chemometec). The cells 
were counted using a Mammalian Cell Counter NucleoCounter® NC-100™ 
(Chemometec). 
2.7 In vivo B16F10 subcutaneous tumour model 
The cells were counted and resuspended at 5x106 cells/ml in serum and antibiotic free 
RPMI (Merck). Cells were kept at 37°C. 4-8 week old female C57BL6J mice (Envigo, 
UK) had their left flank shaved. 200μl of cell solution (1x106 cells) was injected into 
the left flank using a 26 gauge syringe [300]. Subcutaneous tumour volumes were 
monitored daily and measured using a Vernier callipers. Tumour volume 
measurements were calculated using the equation: volume= ab2π/6. Where a is the 
largest diameter of the tumour and b is the greatest diameter of the tumour 
perpendicular to a. 
2.8 Isolation of murine blood for flow cytometry 
Blood samples were taken at different times during tumour growth, using volume as a 
measure of tumour development. Mice were anaesthetized with intraperitoneal 
delivery of ketamine (75mg/kg, Chanelle) and Medetomidine (1mg/kg, Chanelle) in 
PBS. 200μl 0.5M EDTA taken up by a 27 gauge syringe to prevent clotting. Blood 
was isolated by cardiac puncture. The blood was kept at room temperature and red 
blood cell (RBC) lysis was performed within 90min. The volume of RBC lysis buffer 
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added (155mM NH4Cl (Merck), 12mM NaHCO3 (Merck), 0.1mM EDTA) was greater 
than 10x the volume of blood obtained. RBC lysis buffer was left to incubate for 7min 
at RT with continuous agitation. The cells were then washed in fluorescence-activated 
cell sorting (FACS) buffer (2% FCS, 0.1% sodium azide (Merck) and 1mM EDTA in 
PBS). RBC lysis was repeated if RBC contamination was visible. 
2.9 Development of BMDMs 
Healthy 4-8 week old female C57BL6J were euthanized humanely by cervical 
dislocation. Tibia and femur bones were isolated. Muscle, cartilage and other material 
was removed from the bone. Bones were transferred to a laminar flow hood to 
maintain sterility and placed in 100% ethanol (Brenntag) for 90 seconds to sterilize 
the surface of the bones. The bones were then transferred to PBS. Both ends of the 
bone were removed using sterile scissors. The bone marrow was then flushed from the 
bone with RPMI supplemented for macrophages (mRPMI) (RPMI supplemented with 
10% FCS, 1% P/S, 0.01mM β-mercaptoethanol (Merck), 1mM sodium pyruvate 
(Merck) and 1x Eagle’s modified essential medium (MEM) non-essential amino acids 
(Merck)) using a 26 gauge syringe (Braun) and passed through a 70μm filter (BD 
Falcon) to obtain a single cell suspension. Cells were washed in mRPMI. All 
centrifugation of BMDM populations was performed at 270g for 7min. The cells were 
resuspended in 50ml RBC lysis buffer (155mM NH4Cl, 12mM NaHCO3, 0.1mM 
EDTA) at RT for 8min with continuous agitation. Cells were washed and resuspended 
in 10ml mRPMI. Cells were counted and resuspended at a concentration of 5x105 
cells/ml in mRPMI supplemented with 50ng/ml recombinant carrier free mouse 
Macrophage colony-stimulating factor (M-CSF, Biolegend) [301,285]. Cells were 
seeded in either 10cm bacteriological petri dishes (Sarstedt) with 10ml of cell solution 
added or in 35mm suspension dishes (Sarstedt) with 1.81ml of cell solution added. 
Cells were left undisturbed at 37°C in a humidified chamber with 5% CO2 for 5 days 
unless otherwise specified. 
2.10 Development of B16F10 conditioned media 
To generate B16F10 conditioned medium (B16CM) 2x106 B16F10 cells were seeded 
in 20ml RPMI supplemented with 2% FCS and 1% P/S. For no treatment controls 
(NTCM) 20ml of RPMI was supplemented with 2% FCS and 1% P/S with no cells 
added. Flasks were incubated for 48hrs at 37°C. Supernatants were isolated and 
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centrifuged to remove any cells or cellular debris. Supernatants were stored at 4-8°C 
for a maximum of 48hrs. Either B16F10 conditioned medium (B16CM) or No 
treatment concentrated medium (NTCM) was added to Vivaspin 20 
ultracentrifugation tubes (GE Healthcare) with a molecular weight cut-off (MWCO) 
of 3,000Da and centrifuged at 8000g for 1-3hrs until was reduced to 0.5-0.8ml 
[302,303]. Ultracentrifugation with a MWCO filter of 3,000Da allowed the retention 
of all proteins greater than 6,000Da in size. Medium, including salts and other 
components under 6000Da in size can pass through the MWCO filter and into the 
lower chamber, while the remaining fluid containing components of 6000Da or larger 
was retained and concentrated in the upper chamber. B16CM and NTCM were used 
to treat BMDMs at a final concentration of 1x, as shown in figure 2.1. 
2.11 Harvesting of BMDMs 
Different methods were used to isolate cells and samples depending on the assays 
which were to be performed. 
When cell viability was required, such as for reseeding cells or flow cytometry, the 
supernatant was isolated, and the dish was rinsed once in PBS, the PBS was retained 
along with the supernatant.  
 
 
Figure 2.1 Protocol for the development of melanoma conditioned macrophages. 
B16F10 cells were grown in RPMI with 2% FCS and 1% P/S for 48hrs. The supernatant was isolated 
and ultracentrifuged with a MWCO filter for 3kDa. Separately BMDMs were generated from the bone 
marrow of healthy 4-6 week old C57BL6J mice by culturing the cells in M-CSF. Following 5 days of 




Adherent cells were isolated by adding 5mM EDTA in PBS and incubating on ice for 
5min. These cells were added to the suspension cells. Isolation of all cells from each 
dish was confirmed by light microscopy, and if necessary a further incubation in 
EDTA on ice was performed. 
Where only supernatant was required, such as for Enzyme-linked immunosorbent 
assays (ELISA) or Griess assays, the supernatant was gently lifted from the dish 
minimizing agitation of cells. The supernatant was then washed at 500g for 5min to 
remove cells and cellular debris from the supernatant. Assays were performed 
immediately where possible or supernatant was stored at 4°C for up to 24hrs or at -
20°C for up to 7 days. 
When cell viability was not required, such as prior to analysis by quantitative 
polymerase chain reactions (qPCRs) or arginase assays, cells were isolated with a cell 
scraper to detach adherent cells. Cells were then washed twice in PBS before cell lysis 
in an assay dependent lysis buffer (specified in relevant protocols). Following cell 
lysis, a Bradford Assay (see below) was performed to normalize the protein 
concentration of cell lysates. 
2.12 Flow cytometry 
Cells were washed in FACS buffer and 1x106 cells were transferred to FACS tubes 
(BD Biosciences). Cells were resuspended in 500μl blocking buffer (1 part FACS 
buffer to 1 part FCS) and incubated for 10min at RT. The cells were washed twice in 
FACS buffer. All flow cytometry wash steps are defined as the addition of 2ml of 
FACS buffer to each tube and centrifuging at cell type specific speed for 5min, after 
decanting the supernatant, the cells were vortexed to resuspend. Fluorescently 
conjugated antibodies (Table 2.4) were added to the cells (suspended in 100μl of 
FACS buffer remaining after discarding the rest of the FACS buffer). Where possible 
master mixes of antibodies were prepared in advance of use. Once antibodies were 
added, FACS tubes were kept in the dark.  Cells were incubated at RT for 20-30min 
and washed twice.  
Where granzyme B staining was required, surface markers were stained first. Cells 
were fixed in 2% paraformaldehyde for 20min. Cells were washed 3 times in 
67 
 
Intracellular staining permeabilisation wash buffer (Biolegend) and granzyme B-PE-
Cy7 antibody was then added for 30min. Cells were washed twice in FACS buffer. 
Cells were resuspended in 200-500μl FACS buffer and read on a custom BD flow 
cytometer (Table 2.5).  
 












CD11b (M1/70) BV 605 Rat IgG2b,κ 0.75 BD Biosciences 
Ly6C (HK1.4) Pacific Blue Rat IgG2c,κ 1 Biolegend 
Ly6G (1A8) FITC Rat IgG2a,κ 1.5 BD Biosciences 
CCR2 (475301) APC Rat IgG2b 2 R&D Biosystems 
CD115 (AFS98) PE-Cy7 Rat IgG2b,κ 1 Invitrogen 
F4/80 (BM8) PE Rat IgG2a,κ 1 Biolegend 
CD206 (C068C2) PerCP/Cy5.5 Rat IgG2a, κ 1 Biolegend 
Granzyme B 
(QA16A02) 
PE-Cy7 Rat IgG1, κ 3 Biolegend 
CD3 (C363.29B) PE Rat IgG2b, κ 1 Novusbio 
CD4 (RM 4-5) FITC Rat IgG2a, κ 1 eBioscience 
CD8 (53-6.7) FITC Rat IgG2a, κ 1 Biolegend 
CXCR3 (CXCR3-
173) 
PE-Cy7 Armenian hamster IgG 1 eBioscience 
CD25 (PC61.5) APC Rat IgG1, λ  eBioscience 
Primary antibodies were used to identify specific protein targets in murine immune cells and murine 
bone marrow-derived cells by flow cytometry. Listed above are the targets of each antibody, the clone 
of the antibody, the fluorochrome to which the antibody was bound, the isotype of the antibody constant 
domain, the volume which was added to stain cells, and the suppliers of each antibody. C-X-C 
chemokine receptor type 3 (CXCR3), brilliant violet 605 (BV605), Fluorescein isothiocyanate (FITC), 
propidium iodide (PI), phycoerythrin (PE), phycoerythrin- cyanine7 (PE-Cy7), Peridinin-chlorophyll-







Compensation controls were performed on anti-rat anti-hamster Ig κ negative and 
positive CompBeads (BD biosciences). 1 drop of positive and negative beads were 
mixed and 1μl of each antibody was added to the relevant single stain control tube. 
Single stain controls were run for each new experiment and used to set up the 
compensation controls. Each single stain control was used to gate a true positive and 
negative signal for each fluorochrome. Successful compensation was confirmed with 
the use of fluorescence minus one control tubes, performed on cells. Isotype controls 
and unstained controls were run for every experiment. The same volume of isotype 
control antibody was added as of the corresponding antibody and the cells were 
incubated for the same length of time as the experimental tubes.  
Results were analysed on FlowJo® software (version 10.5.0). Positive staining was 
determined by comparison to both unstained and isotype control antibodies. All 
experiments included an initial gate which excluded doublets by comparison of height 
and width of forward scatter (FSC) readings. Subsequently FSC and side scatter (SSC) 
low events were excluded from analysis to gate out non-cellular debris (Figure 2.2). 
Isotype controls and gating strategies for all flow cytometry graphs are shown 
(Figures 2.3-2.9). Axes in flow cytometric graphs are ‘logicle’ scaled and not 
logarithmically scaled, except for forward and side scatter (FSC and SSC) which are 













Table 2.5 Lasers, filters, channels and fluorophores detected on a custom BD LSR flow 
cytometer used for all experiments. 





UV 355nm 505LP 525/50  
 450/50  
Violet 405nm 595LP 610/20 BV605 
505LP 525/50  
 450/50 Pacific Blue 
Blue 488nm 505LP 525/50 FITC 
675LP 685/35 PI, PerCP/Cy5.5 
Yellow/Green 
561nm 
755LP 780/60 PE-Cy7 
685LP 710/50  
635LP 660/20  
600LP 610/20  
 582/15 PE 
Red 640nm 735LP 780/60  
685LP 710/50  
 670/14 APC 
A flow cytometer was used to identify specific populations of immune cells. The flow cytometer was a 
custom BD LSR flow cytometer in which the filters and channels were specifically chosen. Above is a 
list of the lasers, filters and channels used to identify the presence and level of antibody staining. *Long 
pass (LP), Brilliant violet 605 (BV605), Fluorescein isothiocyanate (FITC), propidium iodide (PI), 
phycoerythrin- (PE), phycoerythrin- cyanine7 (PE-Cy7), Peridinin-chlorophyll-protein complex 
(PerCP), Allophycocyanin (APC). 
 
Figure 2.2 Exclusion of doublets and debris from flow cytometric data 
Prior to flow cytometry analysis, singlets were gated by comparison of FSC-area and FSC-height as 
shown (left). Subsequently debris was excluded by gating all events except those with a near zero size 





Figure 2.3 Gating of circulating monocyte populations 
Flow cytometry graphs showing the gating strategy used to identify CD11b+ F4/80+ Ly6G- cells in 
peripheral murine blood and the subsequent stratification of these cells into CCR2+ Ly6Chi, CCR2- 
Ly6C+ and CCR2- Ly6C- populations (top) as seen in figure 4.1. Also shown are the isotype controls 
used to determine positive staining (bottom). 
 
Figure 2.4 Gating of monocytic cells from BMDMs for CD206 analysis 
Flow cytometry graphs showing the gating strategy used to identify CD11b+ cells from treated BMDMs 




Figure 2.5 Gating of monocytic cells from BMDMs for CD115 analysis 
Flow cytometry graphs showing the gating strategy used to identify CD11b+ cells from treated BMDMs 
(top), along with representative graphs of treatment groups showing the gating strategy to identify 
F4/80+ CD115- and F4/80+ CD115+ populations across treatment conditions (middle and bottom), which 




Figure 2.6 Gating used to identify CD115+ F4/80hi BMDMs following electroporation 
BMDMs were isolated 72hrs after treatment. Cells were gated as CD11b+ (top).  Cells were then 
identified as CD115- F4/80+ or CD115+ F4/80hi. Shown are isotype control staining and representative 
images of BMDMs treated passively or with EP which were used to determine gating of distinct 


















2.13 Bradford Assay 
Bradford assays were performed to normalise cell lysates by protein content [304]. 
Protein standards, 0-55μg/ml in 5μg/ml increments, were made using a 1mg/ml BSA 
in ddH20 solution. 800μl of samples and standards were added to 1.5ml Eppendorfs. 
200μl Protein Assay Dye Reagent Concentrate (Bio-Rad) was then added to each 
Eppendorf. Eppendorfs were vortexed vigorously and 200μl of each sample was added 
in triplicate to a flat bottom, optically clear 96 well plate. The absorbance of the wells 
was measured at 595nm using a SpectraMax M2 (Molecular Devices). 
2.14 Arginase assay 
Cells were washed twice in PBS and lysed by the addition of 10mM Tris-HCl pH7.4, 
1x cOmplete™ EDTA-free protease inhibitor cocktail (Roche) and 1% Triton X-100 
(Merck) for 30min on ice with vigorous vortexing every 10min. To make 1M Tris-
HCl, 12.1g Trizma® base (Merck) was added 80ml ddH2O. The solution was brought 
to pH7.4 with HCl and the volume was made up to 100ml with ddH20. This was diluted 
1 in 100 in ddH20 on the day of use to make a 10mM solution.  
The samples were centrifuged at 13,000g for 20min to remove any cellular debris from 
the solution. A Bradford assay was performed to normalize the protein concentration 
of cell lysates. Each sample was seeded in sextuplicate. 40μL of cell lysate was added 
to each well. 
An arginase assay kit was used to assay arginase activity of cell lysates (Merck-
MAK112). For each sample 3 wells were run as samples, and 3 samples were run as 
sample blank wells. Sample blank wells were incubated in the absence of substrate 
buffer (supplied in kit) and acted as negative controls in which there is no arginase 
activity [305]. 
As positive and negative controls, 3 wells were seeded with 50μl 1mM urea standard 
(supplied in kit) and 3 wells were seeded with 50μl ddH20.  
10μl of substrate buffer (supplied in kit) was added to each sample well and each 
sample well blank received no addition. The plates were mixed well and sealed to stop 
evaporation. Plates were incubated at 37°C for 2hrs. 200μl of urea reagent (supplied 
in kit) was added to all wells and 10μl of substrate buffer was added to the sample 
blank wells. The plates were incubated at RT for 60min. If turbidity appeared in the 
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wells, the plate was centrifuged at 200g for 5min and the supernatants were transferred 
to a new plate without agitation of precipitate at the bottom of the wells. The 
absorbance was read at 430nm using a SpectraMax M2 (Molecular Devices). In this 
assay, arginase catalyses the conversion of arginine to urea and ornithine. The urea 
produced reacts with the colour development reagent to generate a coloured product 
proportional to the arginase activity present, the comparison of sample wells which 
received substrate buffer before incubation at 37°C and sample blank wells which only 
received substrate buffer following incubation at 37°C permits a calculation of the 
level of arginase activity from each sample. 
2.15 Griess assay 
Supernatants of BMDM treatment cultures were isolated. Supernatants were 
centrifuged at 500g for 5min to remove any cells or cellular debris from the solution. 
A 100μM nitrite standard was prepared using a 1 in 1000 dilution of a 0.1M sodium 
nitrate (Merck) in ddH2O. 100, 50, 25, 12.5, 6.25, 3.125 and 1.5625μM standards were 
prepared using a serial dilution in ddH2O. 50μl of supernatant and standards were 
added in triplicate to flat bottomed optically transparent 96 well plates (Sarstedt). 50μl 
of control media was plated in triplicate. 1% sulphanilamide was made by dissolving 
1g sulphanilamide (Merck) in a solution of 1 part 85% phosphoric acid (Merck) to 16 
parts ddH20. 50μl 1% sulphanilamide solution was added to each well, plates were 
mixed well and stored in the dark at RT for 10min. 50μl 0.1% (w/v) N-1-
napthylethylenediamine dihydrochloride (NED, Merck) in ddH20 solution was added 
to each well, the plate was mixed well and stored in the dark at RT for a further 10min. 
The absorbance of each well was read at 535nm on a SpectraMax M2 (Molecular 
Devices) plate reader within 30min [306]. 
2.16 RNA extraction 
RNA extraction was performed using RNeasy plus minikit (Qiagen). All reagents used 
were contained in this kit unless specified. Following trypsinisation, cells were washed 
3 times in PBS. To lyse the cells 350μl RLT buffer was added to the cell pellet and 
vortexed for 1min. To eliminate the presence of genomic DNA in the product, the cell 
lysate was transferred to a genomic DNA (gDNA) eliminator column and centrifuged 
at 8,000g for 30sec. The flow through was collected and added to an equal volume of 
70% ethanol to provide appropriate conditions for the binding of RNA to the RNeasy 
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spin column. The samples were mixed well and transferred to an RNeasy spin column. 
The column was placed in a 2ml collection tube and centrifuged at 8,000g for 15sec. 
The flow through was discarded and a series of solutions are sequentially added to 
wash the spin column. 700μl of buffer RW1 was added to the spin column. The column 
was centrifuged at 8,000g for 15sec and the flow through discarded. 500μl of buffer 
RPE was added to the spin column. The column was centrifuged at 8,000g for 15sec 
and the flow through discarded. Another 500μl of buffer RPE was added to the spin 
column. The column was centrifuged at 8,000g for 2min and the flow through 
discarded. The spin tube was removed and placed in a new collection tube and 
centrifuged for a further 1min at 8,000g to completely dry the tube and prevent 
contamination of the RNA product with RPE buffer. RNA was then eluted from the 
spin column by adding 30-50μl RNase free water and centrifuging for 1min at 8,000g. 
2.17 DNA and RNA quantification 
Both RNA and DNA content were measured using a NanoDrop spectrophotometer. 
1μl of RNA or DNA solution was placed on the stage of the spectrophotometer for 
measurement. The stage was washed with RNase/DNase free ddH2O before use and 
between samples. The spectrophotometer was zeroed with the same stock of 
RNase/DNase free ddH2O in which the samples were prepared. Both RNA and DNA 
absorb at 260nm. The A260/280 was confirmed to be within 0.1 of 1.8 (for DNA) or 
2 (for RNA)  in all samples, as many protein, phenol and other common contaminants 
absorb strongly at or near 280nm, and thus this is a measurement of DNA or RNA 
purity. The A260/230 values were also confirmed to be within the range of 2.0-2.2. 
Common contaminants from DNA and RNA extraction kits can absorb at 230nm and 
these contaminants can impair the efficacy of downstream applications. Following 
RNA/DNA concentration measurements, the samples were normalized to a maximum 
concentration of 60ng/ml for RNA or 100ng/μl for DNA. 
2.18 Reverse Transcription 
RNA samples were normalized with RNase free water following the determination of 
RNA content by NanoDrop analysis (section 2.16). Reverse transcription was 
performed in 20μl reaction volumes using an Omniscript Reverse Transcriptase kit 
(Qiagen) with 1μM oligo(dt)15 (Promega) and 1μM random hexamers (Qiagen) for 
60min at 37°C. A mixture of oligo nucleotides and random hexamers were used as 
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primers to ensure reverse transcription of transcripts with a diversity of lengths and 
from diverse start points in an effort to ensure samples were not enriched for any 
genes. 
2.19 Quantitative PCR (qPCR) 
Complementary DNA (cDNA) samples were normalized with DNase free water 
following the determination of DNA content by NanoDrop analysis. Primers were 
designed based on publically available genetic sequences and by using the IDT primer 
design tool (Integrated DNA Technologies, Inc). Two sets of primers were synthesized 
by IDT for each gene of interest, one with a short amplicon and one with a long 
amplicon. Primers were validated by visualization of a DNA bands on a 2% agarose 
gel following PCR amplification of BMDM samples and electrophoresis. qPCR was 
performed using Luna® Universal qPCR Master Mix (New England Biolabs) with 
500nM of forward and reverse primers (Table 2.6) and 100ng cDNA. Reactions were 
analysed on an AriaMx Real-time PCR System (Agilent). The thermal profile used 
included a hot start of 3min at 95°C followed by 40 amplification cycles. Each 
amplification cycle consisted of denaturation for 15sec at 95°C, followed by annealing 
for 15sec at 52.5°C and elongation for 30sec at 60°C. A melting curve was performed 
(30sec at 95°C, 30sec at 65°C and 30sec at 95°C) at the end of each analysis to confirm 
efficiency of the primers. 
Data presented was normalized using the 2^ΔΔCT method with normalization to the 
housekeeping gene β-actin. Data was also analysed using glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) to ensure validity of results, no changes in trends or 












Table 2.6 Primers used for qPCR experiments 
Protein Gene Direction Sequence (5’-3’) 
Β-actin ACTB Fwd GAG GTA TCC TGA CCC TGA AGT A 
  Rev GCT CGA AGT CTA GAG CAA CAT AG 
GAPDH GAPDH Fwd CGA GAA ACC TGC CAA GTA TGA 
  Rev CCT GTT GCT GTA GCC GTA TT 
IL-6 IL6 Fwd CTT CCA TCC AGT TGC CTT CT 
  Rev CCT TCT GTG ACT CCA GCT TAT C 
Arginase ARG1 Fwd GAA CTG GCT GAA GTG GTT AGT 
1  Rev TAG GAG TAG GAA GGT GGT CAT AG 
CD206 MRC1 Fwd GTG GTC CTC CTG ATT GTG ATA G 
  Rev AGT GGC TTA CGT GGT TGT T 
Ym1 CHIL3 Fwd CAG GCC AAT AGA AGG GAG TTT 
  Rev GAG TAG CAG CCT TGG AAT GT 
IL-10 IL10 Fwd GGA GCA GGT GAA GAG TGA TTT 
  Rev TCC AAG GAG TTG TTT CCG TTA G 
TGF-β TGFB Fwd CTG AAC CAA GGA GAC GGA ATA C 
  Rev CTC TGT GGA GCT GAA GCA ATA G 
IL-12b IL12B Fwd GCA AGC TCA GGA TCG CTA TTA 
  Rev AGA AGG CCC TGG TTT CTT ATC 
CD68 CD68 Fwd GAT TGA GGA AGG AAC TGG TGT AG 
  Rev CTT CCA CCC TGA ATT GGG TAT AG 
Above are complementary DNA sequences used to identify specific murine mRNA sequences. mRNA 
was isolated, reverse transcribed, amplified and measured to determine relative gene expression in bone 











2.20 BMDM and CD4+/CD8+ T cell cocultures 
Spleens were isolated from healthy 4-8 week old female C57BL6J mice and passed 
through a 70μm filter. RBCs were lysed in RBC lysis buffer (see section 2.8) and 
CD4+ or CD8+ T cells were isolated using negative selection magnetic bead labelling 
kits (Miltenyi Biotec) according to the manufacturer’s instructions. Splenic cells were 
washed once in separation buffer (PBS with 0.5% BSA). All solutions, including 
separation buffer, separation kit reagents, and splenic cells, were kept on ice during 
separation. The following volumes are per 1x107 cells, where more starting cells were 
used for isolation the volumes added were scaled appropriately. Cells were 
resuspended in 40μl separation buffer and 10μl of Biotin-Antibody Cocktails 
(supplied in kit) were added. Cells were vortexed and incubated on ice for 5min. A 
further 30μl of separation buffer and 20μl of Anti-Biotin MicroBeads (supplied in kit) 
were added. Cells were vortexed and incubated on ice for 10min. During incubation, 
an LS column (Miltenyi Biotec) containing magnetic beads was placed in a 
QuadroMACS™ Separator magnet (Miltenyi Biotec) and was washed by adding 3ml 
of separation buffer. The run through was discarded. The column was kept wet at all 
times, adding additional separation buffer when required to prevent the column 
running dry. Following 10min incubation with Anti-Biotin MicroBeads, the cell 
solution was added to the LS column. The flow through containing unlabelled cells 
was collected. The column was rinsed with a further 3ml separation buffer and the run 
through was added to the negatively selected faction representing enriched CD4+ or 
CD8+ T cells.  
In each kit all other cells are selected for by the cocktail of antibodies provided in the 
Biotin-Antibody Cocktail solution, these cells are bound by biotin-avidin reactions to 
magnetic microbeads and retained in the LS column while the CD4+ or CD8+ T cells 
are free to pass through. Once the LS column is removed from the magnetic field, 
these positively selected cells can be eluted from the LS column. These cells were not 
required for further use in the experiments performed in this thesis. 
Following separation, the negatively selected T cells were washed once in PBS. Cells 
were then resuspended in 2ml 5μM carboxyfluorescein succinimidyl ester (CFSE) in 
warm PBS for precisely 8min. Cells were then washed in cRPMI 3 times. 
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Confirmation of separation and CFSE analysis was performed by flow cytometry. An 
aliquot of cells was taken pre-separation and an aliquot of the negatively selected 
faction were taken both before and after CFSE staining. The cells were stained with 
PE conjugated CD4 or CD8. The concentration of CD4+ or CD8+ T cells was 
confirmed to be above 85% in all negatively selected T cell enriched samples before 




Figure 2.7 Concentration and CFSE staining of CD4+ or CD8+ T cells following magnetic bead 
separation and CFSE labelling 
Aliquots of T cells were taken before magnetic bead separation, post magnetic bead separation and post 
CFSE staining. All aliquots were stained for FACS analysis with either CD4-PE or CD8-PE. Cells were 
gated by FSC and SSC to remove debris from analysis (top). Cells were then gated based on CD8 
expression (middle row). All samples were confirmed to be >85% purity prior to further use. CFSE was 





Figure 2.8 Identification of CD4+ T cell purity and gating of CFSElo cells following coculture 
Flow cytometry graphs showing gating strategy used to identify CD4+ T cells following coculture (top) 
and to differentiate proliferating T cells (bottom) seen in figures 4.8 and 5.6. 
 
Figure 2.9 Gating used to identify CD8+ T cell proliferation 
Flow cytometry graphs showing representative graphs of the gating strategy used to gate for CD8+ T 
cells (top) seen in figures 4.9 and 5.7. Also shown is the CFSE staining of a T cell only aliquot and a 
sample coculture reaction, showing gating of cells which have proliferated (bottom). 
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Before the coculture experiments BMDMs were treated for 24hrs and washed 3 times 
to prevent contamination of coculture reactions with treatment conditions. CFSE 
stained T cells were cocultured with pre-treated and washed BMDMs at a 
concentration of 5x105/ml T cells and 5x105/ml BMDMs in 200μl reactions in round 
bottom suspension 96 well plates (Sarstedt) to ensure the aggregation of T cells and 
BMDMs [307]. The cocultures were incubated at 37°C for 5-7 days. Harvesting of 
experiments was timed by checking for the presence of significant T cell proliferation 
as determined by a decrease in CFSE staining in positive control sample wells (Figure 
2.8-2.9).  
2.21 Reversible Electroporation 
Cells were trypsinised, counted and aliquoted into polystyrene FACS tubes (BD 
biosciences) with 2x106 cells added to each tube. The cells were washed once in 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) EP buffer (10mM HEPES 
(Merck), 250mM Sucrose (Merck), 1mM MgCl2 (Merck) in ddH20) and resuspended 
in a final volume of 1.6ml of EP buffer with or without calcium (Merck) or bleomycin 
(Mylan). 800μl of the 1.6ml was added to an electroporation cuvette (VWR).  
For all experiments involving calcium, Milli-Q® ultrapure water from a Milli-Q® 
Integral Water Purification System for Ultrapure Water (Merck) was used instead of 
ddH2O, to ensure buffers had no calcium contamination. 
Cells were electroporated at room temperature in 0.4cm cuvettes (Fisherbrand) at 
700V/cm (280V across 0.4cm), unless specified, using 8 square wave pulses of 99μsec 
at 1Hz using a BTX ECM 2001 square wave electroporator (BTX, San Diego, USA) 
[308]. For no electroporation controls, cells were left in FACS tubes at RT while other 
cells were subjected to electroporation. Following electroporation all cells were placed 
at 37°C for 20-40min to allow electroporated cells to recover their cell membrane 
integrity following electroporation. Following incubation, the inner surfaces of the 
electrodes were vigorously washed and the cells were transferred to a new FACS tube. 
Cells were washed in cRPMI and resuspended in 1ml of cRPMI. Cells were then 
seeded in 6 well plates with 2ml media and incubated at 37°C in a humidified chamber 
with 5% CO2 for 24hrs.  
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2.22 Colony forming assay 
Following electroporation the cells were seeded for 24hrs to allow cells to recover. 
The cell concentration was determined empirically for each treatment to ensure 60-
90% confluency of cells after 24hrs. Supernatants and non-adhered cells were 
discarded to select for adherent (viable) cells. Cells were counted and resuspended at 
a standardized concentration of 400 cells/well in cRPMI. 4ml of cell solution was 
added to each well of a 6 well plate. All samples were run in triplicate. The plates were 
incubated at 37°C in a humidified chamber with 5% CO2 for 10-14 days until visible 
colonies were established in the no treatment control well [309]. The supernatant was 
removed from the wells and 3-4ml of methanol (Honeywell) was added to each well 
for 5-10min. Methanol was removed and Prodiff stain 2 (Acquascience), composed of 
buffered methyl thionins, was added to the wells so that the entire surface of the well 
was covered for 5-10min. Prodiff solution was removed and the plates were washed 
under running ddH20. Plates were allowed to dry for 1-2 days. Once fully dry the 
underside of the plates was cleaned with 70% ethanol spray (Brenntag) to remove any 
marks from the underside of the plate. The fluorescence of the plate was then read 
using a Li-Cor plate reader (Odyssey) at 800nm. 
2.23 Enzyme-linked immunosorbent assay (ELISA) 
Mouse Interferon γ (IFNγ), IL-4 and IL-10 ELISA Max™ Deluxe Sets (Biolegend) 
were used for ELISAs according to the manufacturer’s instructions. Coating buffer A 
was made by mixing 4 parts ddH20 with 1 part 5x Coating buffer (supplied in kit). 
Capture antibody (supplied in kit) was diluted 1 in 200 in 1x coating buffer. Nunc™ 
MaxiSorp™ ELISA plates (supplied in kit) were coated with 100μl per well of diluted 
capture antibody, sealed with cling film and stored overnight at 4°C. The capture 
antibody was emptied from the plate and the plate was washed. For each wash step the 
plate was washed 4 times in wash buffer (PBS + 0.05% Tween (Merck)). Assay diluent 
was made by diluting 1 part 5x assay diluent (supplied) with 4 parts PBS. The plate 
was blocked by adding 200μl assay diluent to each well. The plate was sealed and 
placed on a plate shaker at 500rpm with a 0.3cm orbit for 1hr at RT, all subsequent 
incubation steps were performed with the plate sealed and on a shaking incubator at 
RT. The antibody diluent was eluted and the plate was washed.  
83 
 
Standards were made by reconstituting 1 vial of standard (supplied in kit) in 200μl 
assay diluent. These solutions were diluted in assay diluent to generate serial dilutions 
to be used as standards. IFNγ standards were made at 2000, 1000, 500, 250, 125, 62.5 
and 31.25pg/ml. IL-4 standards were made 125, 62.5, 31.25, 15.63, 7.8, 3.9 and 2.0. 
IL-10 standards were made at 1000, 500, 250, 125, 62.5, 31.25 and 15.63pg/ml. Assay 
diluent alone was used as a negative control.  
100μl of supernatants and standards were added to the appropriate wells in triplicate 
and the plate was incubated for a further 2hrs. The samples were eluted and the plate 
was washed. Detection antibody was made by diluting the 200x detection antibody 
(supplied) in assay diluent. 100μl diluted detection antibody was added to each well 
and the plates were incubated for 1hr. Detection antibody was eluted from the plate 
and the plate was washed. Avidin- Horseradish peroxidase (HRP) solution was made 
by diluting the 1000x Avidin-HRP (supplied in kit) in assay diluent. 100μl diluted 
Avidin-HRP solution was added to each well and the plate was incubated for 30min. 
Avidin-HRP was eluted from the plate and the plate was washed.  Equal volumes of 
substrate solution A (supplied in kit) and substrate solution B (supplied in kit) were 
mixed to make 3,3′,5,5′-Tetramethylbenzidine (TMB) substrate. 100μl of TMB 
substrate was added to each well, the plate was tapped to mix well and stored in the 
dark for 15-30min until a strong colour change developed. 100μl 1M HCl stop solution 
was added to each well and the plate was read on a SpectraMax M2 (Molecular 
Devices) plate reader at 570nm and 450nm. The 570nm reading provided a measure 
of non-specific values which were subtracted from the 450nm values before analysis.  
2.24 Statistical analysis 
2.24.1 Chapter 3 
All statistical analyses was carries out in the R environment, v.3.4.4. Boxplots shown 
represent the mean, with interquartile ranges (boxes) and 95% confidence interval 
(whiskers), with outliers shown.  
Spearman’s correlations were used to determine significance, correlation coefficients 
between continuous variables. The Wilcoxon rank sum test was used to determine 
significance between continuous and discrete variables.  
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Where a large number of zero values were obtained in immunohistochemical 
measurements (CD68 staining), semi-quantitative measurements were used for data 
analysis. A Spearman correlation was used in figure 3.2d to show the association of 
intratumoural CD68+ cells with Breslow depth, however the Wilcoxon rank sum test 
value of this association is also presented in table 3.1, both were non-significant. 
Gene expression data was analysed using normalized gene values as presented by 
HTG EdgeSeq technology. Differentially expressed genes between groups were 
detected using the DESeq2 algorithm with adjusted p values. Heat maps were clustered 
using the Ward-Linkage method and generated using the Made4 package v.1.58 within 
the R environment. Kaplan-Meier plots and associated statistical testing was 
performed using the survminer package in R, v.0.4.4. Survival probabilities were 
calculated using the Cox proportional hazards model and differences between groups 
were analysed using the log-rank test. 
2.24.2 Chapter 4 and 5 
Statistical analysis for data present in chapter 4 and 5 was performed using GraphPad 
Prism version 5.03. Flow cytometry data was analysed using FlowJo version 10.5.3. 





















Chapter 3  
Immunohistochemical evaluation of the presence and 

















The density and phenotype of tumour-associated macrophages have been linked with 
prognosis in a range of solid tumours. While there is strong preclinical evidence that 
tumour-associated macrophages promote aspects of tumour progression, it can be 
difficult to infer clinical activity from surface markers and ex vivo behaviour. Here, 
we investigated the association of macrophage infiltration with prognosis and 
functional changes in the tumour microenvironment in primary human melanoma. 57 
formalin-fixed paraffin embedded primary melanomas were analysed by 
immunohistochemical analysis of CD68, CD163, iNOS and arginase expression. RNA 
sequencing was performed on serial sections of 20 of the stained tumours to determine 
the influence of macrophage infiltration on gene expression. CD68+ cells were found 
to be a functionally active subset of macrophages that are associated with increased 
iNOS and arginase staining and altered gene expression within the tumour. In 
comparison, while there is a greater accumulation of CD163+ macrophages in larger 
tumours, these cells are comparatively inactive, with no association with the level of 
iNOS or arginase staining, and no effect on gene expression within the tumour. 
Infiltration of either subset of macrophages did not correlate to overall survival. Thus, 
melanomas contain distinct macrophage populations with diverse phenotypes, but 













Macrophage infiltration as determined by evaluation of FFPE has been shown to be a 
prognostic indicator in a range of solid malignancies [310]. The markers used to 
identify macrophages vary, and there is no consensus on markers which reflect true 
physiological subsets [311]. 
In the majority of cancers the macrophage marker CD163 correlates with more 
advanced tumours and to a worse prognostic outcome, except in the cases of gastric 
cancer and colorectal cancers [36,37,53,310]. Other markers, such as CD68, have been 
used to stain macrophages, but have been linked to both favourable and unfavourable 
outcomes [53,43]. 
Previous studies have attempted to delineate the prognostic influence of macrophage 
infiltration in melanoma. Both the number of CD68+ cells and soluble CD163 have 
correlated to poor OS, however only CD68 counts at the invasive front of the tumour 
were independent predictors of reduced survival [248]. 
Macrophages have been implicated in all aspects of tumour progression including 
proliferation, survival, immunosuppression, angiogenesis and metastasis [312]. 
Furthermore macrophages have been implicated in resistance to various therapies such 
as chemotherapy and radiotherapy [76,79,81,89]. 
However, much evidence of the effect of intratumoural infiltration has been inferred 
from in vitro analysis which is based on the hypothesis that the expression of surface 
markers is reflective of functional phenotype, however it is known the diversity of 
functional phenotypes and macrophage plasticity are controlled by a much more 
intricate underlying system of epigenetics that cannot be represented by the known 
subset of surface markers [268,313]. The precise nature of macrophages continues to 
be unravelled, and during the process of unravelling, further findings continue to add 
additional layers of complexity to an already poorly understood science [200]. 
Recently horizontal transformation from macrophage-like cells to fibroblast-like cells 
has been observed, and the source or stability of discrete populations are still not 
known [60]. As such, macrophage markers may not be considered stable markers of 
distinct cells. However, whether they represent stable populations or a continuous flow 
of cells through a transition state, we can use these markers to identify distinct subsets 
of macrophage-like cells at any point in time. 
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Another source of concern is the discrepancy of results in murine and human 
intervention studies [20]. It is known that monocyte and macrophage markers vary 
between mice and humans, such as F4/80, which is a monocyte and macrophage 
marker in mice, but its homolog, EMR1, is an eosinophil-specific receptor in humans 
[314]. But cross-species differences have also been seen in the outcomes of 
interventions targeting conserved targets. Anti-CSF1R antibodies which inhibit 
macrophage migration to the tumour have been effective in the treatment of murine 
malignancies, however clinical trials have observed no therapeutic benefit in humans, 
indicating a differential physiological role or reliance on macrophage behaviour 
between mice and human disease [310,180,213]. The influence of macrophages on 
tumour biology in human malignancies is not fully known as macrophages are also 
known to adopt unreactive senescent and quiescent states [315]. 
Another central concern is the sensitivity of macrophages to environmental stimuli, 
which adds question to the compatibility of ex vivo studies [316]. Macrophages are 
known to be activated by environmental stimuli including adherence to the 
extracellular matrix and a wide range of innocuous stimuli such as adherence to 
plastic, thus ex vivo studies contain inherent limitations [317,318,316]. An alternative 
approach is to investigate the presence and associations of macrophages in FFPE 
tissues. While this approach reduces the level of artificially introduced environmental 
impacts, it comes with its own experimental limitations. From a clinical standpoint, 
this approach has significant advantages in being able to draw on the existing biobanks 
with associated patient data [319]. 
Here we evaluate the presence of CD68+ and CD163+ macrophages in human primary 
melanoma lesions, and determine their correlation with the canonical M1:M2 enzymes 
iNOS and arginase [320]. To further investigate if these cells have a biological role, 
we investigate their link with OS and determine if they correlate to differential gene 








3.3.1 Correlation of CD68+ and CD163+ macrophage infiltration with 
pathological features of melanoma 
Primary untreated melanoma lesions were stained with CD68 and CD163 antibodies 
to identify macrophages, and with iNOS and arginase to identify enzymatic activity. 
CD68, iNOS and arginase specifically stained cytoplasmic compartments (Figure 
3.1). CD163 stained both the cytoplasm and plasma membrane of target cells, with 
increased staining intensity seen at the plasma membrane. CD68 and iNOS staining 
was specific to cells with a distinct macrophage morphology. CD163 stained a much 
larger number of cells, but was not restricted to cells of a distinct macrophage-like 
morphology. Arginase staining was less frequent and was completely negative in 
almost half of stained sections. In positive sections, stained cells showed a distinct 
macrophage (Figure 3.1e) or neutrophil (Figure 3.1f) morphology, thus arginase 
staining as presented in this study is a reflection of a subset of both neutrophils and 
macrophages. Many ulcerated tumours showed a distinct influx of a high number of 
arginase+ neutrophils to the peritumoural ulcerated tissue. There was a statistically 
significant positive correlation between peritumoural arginase+ cells and ulceration, 
accompanied by a significant decrease in peritumoural CD68+ cell infiltration. 
The number of positive cells per mm2 were measured in both intratumoural tissue and 
peritumoural tissue. 21 specimens were negative for intratumoural CD68+ cells and 30 
were negative for peritumoural CD68+ cells, as such CD68 data was stratified into 
those with and without the presence of stained cells. Previous reports have similarly 
found that tumours of the same subtype may be negative or positive for the presence 
of CD68+ cells [321]. 
There was no significant correlation between the infiltration of CD163+ and CD68+ 
cells, indicating that these cells represent distinct, but potentially non-mutually 
exclusive, macrophage subsets (Figure 3.2a-b). The correlation of CD68 and CD163 
macrophage infiltration with pathological features of the tumour were determined 
using Spearman correlations and Wilcoxon Rank sum tests (Table 3.1). No 
differences in cell density were seen between baseline characteristics such as age, 
gender, tumour stage, or tumour infiltrating lymphocytes. Intratumoural CD163+ 
macrophages were found to increase with Breslow depth (Figure 3.2c). There was a 
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decrease in the number of peritumoural CD68+ macrophages in tumours with a thicker 
Breslow depth (Figure 3.3a), however there was no significant correlation with 
intratumoural CD68+ macrophages and tumour size. The nature of this non-significant 
trend was in contrast to intratumoural CD163+ cells, with the trend suggesting 
potentially decreased numbers of CD68+ cells in tumours with a thicker Breslow depth 
(Figure 3.2d). A reduced number of peritumoural CD68+ cells were also seen in 
ulcerated tumours (Figure 3.3b). 
 
Table 3.1 Association of pathological tumour features with CD68+ and CD163+ 
macrophage infiltration  
 CD68 CD163 
 Peritumoural Intratumoural Peritumoural Intratumoural 
Age (years) 0.4 0.19 0.233 (0.162) 0.502 (0.092) 
Gender 0.425 0.834 0.498 0.78 
Breslow depth (mm) 0.004 0.5 0.937 (0.011) 0.0191 (0.315) 
Stage 0.28 0.72 0.62 0.213 
BRAF status 0.027 0.001 0.443 0.726 
Mitotic count (mm) 0.01 0.13 0.908 (-0.017) 0.501 (-0.017) 
Ulceration (mm) 0.12 0.36 0.074 (0.356) 0.208 (0.255) 
Ulceration (Yes/No) 0.01 0.224 0.549 0.683 
TIL distribution 0.683 0.455 0.166 0.353 
The association of the number of CD68+ and CD163+ cells with patient and tumour characteristics was 
determined using Wilcoxon Rank Sum test and Spearman Correlations. The significance value for each 
relationship is shown above, and where relevant the correlation coefficient between two continuous 
variables is also shown. Data is presented as significance values (correlation coefficients), n=57. With 





Figure 3.1 Staining of primary melanoma tumours 
FFPE tumours were cut and stained by H&E (a), along with immunohistochemical staining of iNOS 
(b), CD68 (c), CD163 (d) and arginase (e-f). Immunohistochemical staining was performed using an 
alkaline phosphatase coupled to Fast-Red to produce a red/pink reaction. Images are shown at 40x (a), 




Figure 3.2 Differential CD68+ and CD163+ macrophage recruitment to primary melanoma lesions 
The number of CD68+ and CD163+ cells were determined by immunohistochemistry in primary 
melanoma tumours. The number of positive cells were counted in the peritumoural and intratumoural 
regions. CD68+ and CD163+ cells were shown to be differentially recruited (a-b). Intratumoural CD163+ 
macrophage infiltration was positively correlated to Breslow depth, while intratumoural CD68+ 
macrophage infiltration showed no significant correlation. Boxplots shown represent the mean, with 
interquartile ranges (boxes) and 95% confidence interval (whiskers), with outliers shown. Correlations 
with discrete variables were analysed using Wilcoxon Rank Sum tests, and between continuous 








Figure 3.3 Reduced peritumoural CD68+ macrophage infiltration in thick and ulcerated 
tumours  
The number of CD68+ macrophages were determined by immunohistochemistry in primary melanoma 
tumours. The number of positive cells were counted in the peritumoural region. a) Tumours with no 
peritumoural CD68+ macrophages had a greater Breslow depth. b) Decreased numbers of peritumoural 
CD68+ macrophages were seen in ulcerated tumours. Boxplots shown represent the mean, with 
interquartile ranges (boxes) and 95% confidence interval (whiskers), with outliers shown. Correlations 
with discrete variables were analysed using Wilcoxon Rank Sum tests, n=57. 
3.3.2 Correlation of CD68+ and CD163+ macrophage infiltration with the 
number of iNOS+ and arginase+ cells 
Given that CD68+ and CD163+ macrophages represent distinct subsets with distinct 
staining profiles based on a number of pathological features, we next set out to 
determine if these differences reflected different immunological profiles within the 
tumour by measuring the expression of the macrophage enzymes iNOS and arginase. 
These enzymes were selected as they are constitutively active when expressed, thus 
they are likely to have a meaningful impact on tumour biology, and they are highly 
cited in the literature, however it must be stated that while these enzymes are 
associated with inflammatory or tissue repair phenotypes respectively, it is important 
not to infer a distinct M1 or M2 phenotype in these cells. Strong positive correlations 
were seen between intratumoural CD68+ macrophages and the number of both iNOS+ 
and arginase+ cells. Specimens with intratumoural CD68+ macrophages had a higher 
level of both arginase+ and iNOS+ cells (Figure 4a-b), while specimens with 
peritumoural CD68+ macrophages also showed a strong increase in peritumoural 
arginase levels (Figure 4c). In contrast, there were no strong positive or negative 
correlations between CD163+ macrophage density and the number of either iNOS+ or 
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arginase+ cells. Intratumoural CD163+ macrophage density was significantly 
correlated to the number of iNOS+ cells showing no meaningful change in the number 
of iNOS+ cells regardless of CD163+ macrophage density (Figure 4d). Thus strong 
differences exist between the correlations of CD68+ and CD163+ macrophage 
populations and iNOS or arginase activity. 
 
 
Figure 3.4 Association of CD68+ and CD163+ macrophage infiltration with iNOS+ and arginase+ 
cells 
The number of CD68+, CD163+, iNOS+ and arginase+ cells were determined by immunohistochemistry 
in primary melanoma tumours. The number of positive cells were counted in the peritumoural and 
intratumoural regions. a-b) Peritumoural and intratumoural CD68+ macrophages were positively 
correlated to the number of iNOS+ cells. c) Peritumoural CD68+ macrophages were found to positively 
correlate to arginase+ cells. d) Intratumoural CD163+ macrophages were found to correlate to the 
number of iNOS+ cells, however the trend line shows that this is a near zero trend. Boxplots shown 
represent the mean, with interquartile ranges (boxes) and 95% confidence interval (whiskers), with 
outliers shown. Correlations with discrete variables were analysed using Wilcoxon Rank Sum tests, and 




3.3.3 Effect of CD68+ and CD163+ macrophage infiltration on total 
intratumoural gene expression 
While an increase in the number of iNOS+ and arginase+ cells in tumours with CD68+ 
macrophages is indicative an active CD68+ macrophage phenotype, both iNOS and 
Arginase activity reflect a very small component of macrophage behaviour which is 
unlikely to independently determine the influence of macrophages on tumour biology. 
To determine if the macrophage infiltration could have an effect on global gene 
expression within the tumour tissue we performed RNA sequencing on serial sections 
of the same FFPE tissue. In addition to seeing no effect of CD163+ macrophage 
infiltration on iNOS or arginase staining, no effect was seen on gene expression within 
the tumour tissue. Analysis of both peritumoural and intratumoural CD68+ 
macrophage infiltration correlated to differential expression of a number of genes 
within the tumour tissue (Figure 3.5). This effect was all the more notable given an 
average of 7-15 fold more CD163+ macrophages in the tumour in comparison to 
CD68+ macrophages. The genes affected were not specific to monocytic cells and were 
reflective of a broad range of processes within the tumour such cell proliferation, cell 





Figure 3.5 The correlation of CD68+ macrophage recruitment with differential gene expression 
The number of CD68+ and CD163+ macrophages were determined by immunohistochemistry in 
primary melanoma tumours. Intratumoural gene expression of the same FFPE blocks was measured 
using next-generation sequencing technology. Using Deseq2 algorithms both peritumoural and 
intratumoural CD68+ macrophages were shown to correlate to differential regulation of a number of 
genes within the tumour. CD68 positive samples are marked as blue along the upper margin, while 
CD68 negative samples are marked as red. Gene associated signalling pathways are colour coded on 
the right hand margin. No effect was observed by the level of CD163+ macrophage infiltration. Data 
was displayed using the Ward-Linkage method for significant genes from a database of 2550 oncology 








3.3.4 Effect of CD68+ and CD163+ macrophage infiltration on OS 
To determine if the markedly different functional phenotypes of CD68+ and CD163+ 
could impact patient outcome we analysed the effect of macrophage density on OS 
(Figure 3.6). No significant correlations were seen in survival probability between 
tumours with or without CD68+ macrophage infiltration or high or low CD163+ 
macrophage infiltration (Figure 3.6a-d). 
Previous studies have showed contrasting prognostic trends of CD68 M1-like and 
CD163 M2-like macrophages in other tumour types such as lung cancer and ovarian 
cancer [51,56]. Non-significant trends of increased intratumoural CD68+ (p=0.2) and 
CD163+ (p=0.052) macrophage density were associated with improved and worse 
survival respectively. These results are in line with previous literature which have 
failed to show a prognostic significance of TAM density in melanoma. 
 
Figure 3.6 Correlation of CD68+ and CD163+ macrophage infiltration with OS 
The number of peritumoural and intratumoural CD68+ and CD163+ macrophages were determined by 
immunohistochemistry in primary melanoma tumours.  Patients were stratified based on the density of 
infiltrating macrophages and survival probabilities were predicted using Cox proportional hazards 
model, and visualised with a Kaplan-Meyer curve. Tumours were stratified as having CD68+ 
macrophages (positive) or having no CD68+ cells present (negative) (a-b). The level of CD163+ 
infiltration was stratified as high or low (c-d). Survival probabilities were calculated using the Cox 




3.3.5 Correlation of iNOS+ and arginase+ cell infiltration with pathological 
features of melanoma 
Having shown the effect of CD68+ and CD163+ macrophage infiltration, we next 
observed if the number of iNOS+ or arginase+ cells independently correlated to 
pathological features of the tumour (Table 3.2). There were no correlations with age, 
gender, Breslow depth, tumour stage, mitotic count or tumour infiltrating 
lymphocytes. BRAF positive tumours were found to have significantly increased 
levels of peritumoural and intratumoural iNOS+ cells (Figure 3.7a-b). Ulceration and 
BRAF status correlated to the number of iNOS+ and arginase+ cells. Notably the 
presence of ulceration resulted in significantly reduced peritumoural and 
intratumoural iNOS+ cells (Figure 3.7c-d) and the presence and size of ulceration was 
positively correlated to the number of arginase+ cells (not shown).  
 
Table 3.2 Association of pathological tumour features with iNOS+ and Arginase+ cell 
density, presented as significance values 
 Arginase iNOS 
 Peritumoural Intratumoural Peritumoural Intratumoural 
Age (years) 0.242 0.861 0.28 0.17 
Gender 0.921 0.721 0.62 0.69 
Breslow depth (mm) 0.947 0.671 0.4 0.2 
Stage 0.894 0.482 0.09 0.16 
BRAF status 0.416 0.693 0.0002 0.0002 
Mitotic count (mm) 0.492 0.084 0.28 0.35 
Ulceration (mm) 0.00015 0.416 0.15 0.67 
Ulceration (Yes/No) 0.795 0.33 0.008 0.005 
TIL distribution 0.278 0.582 0.96 0.77 
The association of the number of arginase+ and iNOS+ cells with patient and tumour characteristics was 
determined using Wilcoxon Rank Sum test and Spearman Correlations. Data is presented as 





Figure 3.7 Correlation of iNOS+ cell density with ulceration and BRAF status 
The number of peritumoural and intratumoural iNOS+ cells were determined by immunohistochemistry 
in primary melanoma tumours.  Shown are significant correlations of iNOS+ cell density with the 
pathological features BRAF status (a-b) and ulceration (c-d). Boxplots shown represent the mean, with 
interquartile ranges (boxes) and 95% confidence interval (whiskers), with outliers shown. Correlations 
with discrete variables were analysed using Wilcoxon Rank Sum tests.  n=57. 
3.3.6 Correlation of BRAF mutational status with CD68+ macrophage 
recruitment and total intratumoural gene expression. 
In addition to the positive correlations of CD68+ macrophages with iNOS+ cells and 
iNOS+ cells with BRAF status, we found that there were a significantly higher number 
of CD68+ macrophages in BRAF positive melanomas (Figure 3.8b-c). BRAF status 
had significant effects on gene expression within the tumour (Figure 3.8a). The genes 
affected by BRAF were independent from the subset affected by CD68+ macrophage 
infiltration, with the exception of VCAM1 and Cyclin-dependent kinase inhibitor 3 
(CDKN3), indicating distinct physiological regulation by CD68+ infiltration and 
BRAF positivity. BRAF positive tumours had upregulated genes involved in 
angiogenesis, cell death and metabolism but down regulated genes associated with 




Figure 3.8 The effect of BRAF status on CD68+ macrophage density and gene expression 
The number of CD68+ macrophages were determined by immunohistochemistry in primary melanoma 
tumours. a) Intratumoural gene expression of the same FFPE blocks was measured using next-
generation sequencing technology. The BRAF status of samples is shown along the upper margin with 
BRAF mutation positive samples marked blue and BRAF negative samples marked red. Using Deseq2, 
genes differentially expressed based on BRAF status were identified. Gene associated signalling 
pathways are colour coded on the left hand margin. Using Wilcoxon rank sum tests it was shown there 
was a higher number of peritumoural and intratumoural CD68+ macrophages in BRAF+ tumours (b-c). 
Data was displayed using the Ward-Linkage method for significant genes from a database of 2550 












Previous reports have cited CD68 as a pan-macrophage marker and CD163 as an M2-
like macrophage marker [322]. Staining of primary melanoma specimens has shown 
that CD68+ cells are significantly less prevalent than CD163+ cells. In many 
melanomas there were no CD68+ macrophages within tumours or peritumoural tissue, 
but there were high levels of CD163+ macrophages across almost all cases. Thus, from 
our study, it is clear that CD68 is not a pan-macrophage marker in melanoma.  
CD68+ and CD163+ macrophages represent distinct physiological subsets [323]. 
While M2 macrophages are commonly regarded as promoting disease progression we 
saw no evidence of a biological role of these cells except an accumulation of cells 
during disease progression, as seen by the positive correlation between intratumoural 
CD163+ macrophages and Breslow depth. Despite the high numbers of CD163+ cells 
(up to 1161 positive cells per mm2), there was no correlation with an increase in iNOS+ 
or arginase+ cells, implying they do not align with traditional M1:M2 phenotyping. 
Furthermore they had no significant effect on gene expression within the tumour, 
indicating that a high number of these cells may not physiologically impact tumour 
biology. While there was a non-significant trend with reduced OS, it is possible that 
this trend is reflective of the increased Breslow depth of tumours with a high number 
of CD163+ cells, and not an independent negative prognostic effect of the cells 
themselves [324].  
Our study cohort was selected from patients who underwent routine BRAF status 
testing and was thus skewed towards advanced melanoma patients. Therefore the lack 
of observed correlations of macrophage markers with tumour stage cannot be 
meaningfully interpreted and will require analysis in an appropriately powered cohort. 
Previous investigations have suggested there is an increase in the density of CD68+ 
macrophages in advanced tumour stages [325]. 
The contrasting trends of CD68+ macrophages and CD163+ macrophages against 
Breslow depth is striking in suggesting a differential expression pattern, albeit with 
the former being non-significantly correlated. There is much evidence that tumours 
exert a strong polarizing effect on recruited cells, and it remains to be determined 
whether the CD68+ and CD163+ infiltration is reflective of differential recruitment, or 
a system in which CD68+ cells are recruited and polarized to a CD163+ phenotype 
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which is less functionally active in the parameters we observed, such as arginase and 
iNOS activity and influencing gene expression within the tumour [326-328]. This 
system would explain both the increased prevalence of CD68+ macrophages in less 
progressed tumours and increased accumulation of CD163+ macrophages in more 
advanced tumours. Previous reports have shown that there is a continuous supply of 
monocytes to diverse tumour types, even tumours such as pancreatic ductal 
adenocarcinoma which has a dense desmoplastic barrier surrounding the tumour tissue 
that can impair cell infiltration, and that tumours exert a strong polarizing effect on 
TAMs to a more M2-like phenotype [174,149,329,330]. 
A high density of intratumoural and peritumoural CD163+ macrophages were detected 
in many tumours however this failed to translate into a difference in global gene 
expression within the tumour tissue. Previous reports have shown an association 
between CD163+ macrophage infiltration and angiogenesis and cyclooxygenase-2 
expression [331]. Specific analysis of these genes with unadjusted p values, which 
may not have been detected by DESeq2 analysis of total gene expression datasets, 
showed no correlation of CD163+ macrophage density with the expression of the 
genes VEGFA/B/C, ANGPT1/2 or PTGS1/2. 
The strong positive correlations between CD68+ macrophage infiltration and the 
number of iNOS+ cells gives strong reason to suggest that these cells are more M1-
like cells [332]. However the positive correlation with arginase+ cells is more 
surprising but possibly representative of a more immunologically active subset 
capable of a range of responses [333]. 
This argument is upheld by the effect of CD68+ macrophage infiltration on gene 
expression within the tumour, in which increased infiltration can impact genes 
involved in a range of processes such as cell death and cell cycle in addition to the role 
of regulation of inflammation.   
While no correlation of CD68+ or CD163+ cell density was found on overall survival, 
non-significant trends were seen which align with previous observations in other 
tumour types in which CD68+ cells can be associated with improved prognosis and 




The increased presence of CD68+ cells and inflammatory markers in BRAF+ tumours, 
could indicate that BRAF status may play a role in determining the response of patients 
to immunotherapies or immunogenic treatments. Recently CD68+ macrophages have 
been found to promote tumour hypoxia and drive resistance to anti-PD-1 antibodies in 
murine models [334]. Conversely, M1-like CD68+ macrophages were also found to 
potentiate the synergistic effects of VEGF inhibitors with BRAF inhibitors in murine 
melanoma [335]. However, clinically CD68 has been found to be a biomarker of 
response to Ipilimumab [108]. Melanoma patients with BRAF mutations were found 
to have a longer progression free survival and higher overall survival in response to 
Nivolumab, with or without Ipilimumab, thus CD68+ macrophages may potentiate the 
favourable effect of BRAF status during treatment with immunotherapies [336]. 
While the two were positively associated, the different genes affected by BRAF status 
and the presence CD68+ macrophages indicate non-redundant roles of BRAF status 
and CD68+ cell infiltration. The p53-DREAM pathway genes CDKN3, DEP domain 
containing 1 (DEPDC1), Survivin, BRCA1 interacting protein C-terminal helicase 1 
(BRIP1), Replication factor C subunit 4 (RFC4) were all strongly associated and down 
regulated in tumours with intratumoural CD68+ macrophage infiltration [337]. None 
of these genes were affected by BRAF status, indicating that this pathway is regulated 
by macrophages. 
The highly active functional phenotype of CD68+ macrophages may indicate CD68+ 
macrophages may be a more viable therapeutic target for therapies looking to boost or 
interfere with TAM behaviour. Previous clinical interventions have targeted CSF1R 
due to the increased prevalence of this receptor and the quality of antibodies which 
can be raised against this target [310]. As CSF1R is a G-protein-coupled receptor 
(GPCR) the opsonisation and depletory effects of targeting are augmented by the 
inhibition of survival signalling in targeted cells [338-340]. Therapeutic targeting of 
CD68 cells has been impeded by the discrepancies between human CD68 and its 
murine homolog, macrosialin, which is not restricted to monocytic cells in mice [341]. 
However, CD68 has been shown to represent differential macrophage subsets to both 
CSF1R and CD163 and thus depletion of CD68+ macrophages, if cell specific 
targeting could be achieved, could improve therapeutic outcomes [342-344].  
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While CD68 has commonly been recognised as a specific monocyte and macrophage 
marker, a major issue with targeting of CD68 is its wide expression in a number of 
cell types [341]. Immunohistochemical analysis and RNA sequencing have shown that 
CD68 levels on fibroblasts and endothelial cells can match levels shown on 
macrophages, and lower levels can be also be detected on tumour cell lines and 
lymphoid cells [342]. This presents major challenges for the effective specific 
targeting of CD68+ macrophages therapeutically. There is merit in investigating if 
other interventions can be developed which can boost the activity or number of CD68+ 
macrophages in the TME. However these results do suggest a hypothesis for the 
clinical failure of anti-CSF1R antibodies, which do not distinguish between CD68+ 
and CD163+ macrophages, and in which the majority of targeted cells are likely to be 


























Chapter 4  
The development of a preclinical model for the study of 
melanoma conditioned macrophages 
Results from this chapter have been published as; 
Tremble LF, Moore AC, Forde PF (2019) Melanoma conditioned medium promotes 
cytotoxic immune responses by murine bone marrow derived monocytes despite their 













Macrophages have been shown to infiltrate a wide range of malignancies and are often 
considered to promote tumour survival, growth and spread. However, the source and 
behaviour of discrete tumour associated macrophage populations are still poorly 
understood. Here we show a novel method for the rational development of bone 
marrow derived monocytes appropriate for the study of processes which involve the 
contribution of circulating inflammatory monocytes. We have shown that in response 
to tumour conditioned medium these cells upregulate CD206 and CD115, markers 
traditionally associated with M2-type macrophages. Treated cells show reduced 
capacity for cytokine secretion but significantly impact CD4+ and CD8+ T cell 
proliferation and polarization. Coculture with conditioned bone marrow derived 
monocytes significantly reduced CD4+ T cell proliferation but increased CD8+ T cell 
proliferation and granzyme B expression with significant induction of IFNγ secretion 
by both CD4+ and CD8+ T cells, indicating that these cells may have a role in 

















The difficulties of in vitro macrophage research have been documented at length [24]. 
At its heart are the inadequacies of current models and uncertainty over whether they 
translate to in vivo physiological behaviour [345]. 
In vivo research of macrophages continues to question basic physiological questions 
such as the native activation state of macrophage populations, the source of distinct 
macrophage populations and the epigenetic or other differences between macrophage 
populations that may influence their behaviour in response to specific environmental 
stimuli, all of which may affect the relevancy of previously published literature. 
The M1 M2 dichotomy of macrophage polarization has been widely used in cancer 
research, with M1 macrophages considered to promote anti-cancer immune responses 
and M2 macrophages supporting tumour survival, growth and spread. TAMs are 
generally considered to be M2-like in nature and thus a negative presence in tumour 
biology. This has been supported by a wide range of studies evaluating the presence 
and phenotypes of macrophages in human cancers, whereby TAMs express M2 
markers and have been associated with poorer prognostic outcomes, with the 
exception of colorectal and gastric cancers [310]. 
The protocols used for the generation of bone marrow derived monocytes and 
macrophages differ widely across the literature. Limited guidelines are available for 
the development of BMDMs, including the growth factors to be used and the source 
of cells [24]. It has been suggested these guidelines in combination with 
comprehensive reporting standards will aid the process of unifying experimental 
protocols and increase the comparability and reproducibility of published research. 
However, there are still a wide range of protocol aspects which vary and which have 
significant impacts on the resultant populations [303,316,346]. 
Monocytes develop into macrophages, however the distinction between monocyte and 
macrophage populations is unclear. Current theories suggest that monocytes migrate 
from the bone marrow to the circulation and exist as two distinct populations. One 
population are primed for inflammatory responses, these cells have been referred to as 
inflammatory monocytes and are defined as CD11b+ Ly6G- Ly6Chi and CCR2+. A 
second population defined as CD11b+ Ly6C+ and CCR2- are commonly referred to as 
non-classical monocytes and are primed for M2 responses [347]. It has been suggested 
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that inflammatory monocytes over time or in the absence of inflammatory stimuli 
evolve into non-classical monocytes [348]. 
In addition to functional differences, these cells also differ in migration potential. 
Inflammatory monocytes rely on CCR2 to home towards the sites of inflammation 
whereas non-classical monocytes rely predominantly on CX3C chemokine receptor 1 
(CX3CR1) and C-C chemokine receptor type 5 (CCR5) expression to direct their 
homing capacity [349]. Both populations are likely to accumulate at tumour sites due 
to leaky vasculature and tumour expression of CCL2, chemokine CX3C motif ligand 
1 (CX3CL1) and Regulated on activation, normal T cell expressed and secreted 
(RANTES, also known as CCL5), the reciprocal ligands for CCR2, CX3CR1 and 
CCR5 respectively. However, it is intuitive that variations will exist between tumour 
types and tumour models, depending on ligand expression and tumour accessibility 
and penetrability. Studies examining the presence of monocytes and macrophages in 
tumour lesions have frequently reported the presence of TAMs which have an M2-like 
phenotype, as was observed in chapter 3. This may in part be due to the shorter half-
life of inflammatory monocytes, recruitment of TAMs from tissue resident subsets 
rather than circulating monocytes, selective proliferation of M2-like TAMs in the 
tumour microenvironment or conditioning by the tumour of monocytes to an M2-like 
phenotype. 
From a tumour immunology point of view the relative contribution of these factors is 
poorly defined and may vary significantly between tumour types, but circulating 
monocytes have been shown to infiltrate murine tumours [350]. 
The type of model in use must also be taken into consideration. Differences exist 
between murine and human cell types, including macrophages, in which cell markers 
can vary significantly [343,351]. The translation of murine models to human disease 
contains inherent limitations. Efforts to decrease these limitations include the use of 
orthotopic tumour models and the use of human cell lines in immunocompromised 
mice, however differences in murine anatomy and the absence of a competent immune 
system still limit the relevance of these models [352-355]. It is still common to use 
subcutaneous tumour models in mice [356,357].  
There are a limited number of cell lines available for the study of murine melanoma. 
Many commonly cited cell lines derivate from a common B16 progenitor, and do not 
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contain BRAF mutations as is commonly reported in human disease [289]. Other cell 
lines have more recently been developed, such as the YUMM lines, which offer a 
selection of transgenic variants for targeted research [288]. The B16F10 cell line is 
one of the most cited murine melanoma cell line due to its aggressive nature in which 
it easily and quickly metastasizes in vivo [289,291]. However, the cell line is poorly 
immunogenic and is commonly transfected with ovalbumin in order to facilitate 
antigen specific cytotoxic CD8+ T cell responses [358]. Subcutaneous B16F10 
tumours have previously been shown by histologic examination to be infiltrated by a 
wide range of immune cells including CD68+ and CD206+ macrophages [359,360]. 
The nature of monocytes and macrophages infiltrating a tumour are likely to impact 
their functional contribution to tumour biology, thus for each tumour type and tumour 
model this must be individually assessed. 
Here we present a concept to bench process for the rational development of an in vitro 
model for the study of monocytes and macrophages in a murine model of melanoma. 
















4.3.1 Prevalence of inflammatory monocytes during murine disease 
Melanomas are one of the most immunogenic cancer types characterized by a high 
volume of tumour infiltrating leukocytes, and are consequently considered one of the 
tumours most likely to benefit from immunotherapy [361].  B16F10 cells are a highly 
aggressive cell line which can be used for the study of murine melanoma. Injected 
subcutaneously they readily form primary tumours which metastasise. We used this 
model of tumour growth to examine the role of TAMs in murine melanoma. 
Circulating monocytes were analysed during tumour growth (Figure 4.1). Monocytes 
were gated as CD11b+ F4/80+ Ly6G- and distinguished as Ly6C+ CCR2- or Ly6C- 
CCR2- non-inflammatory monocytes or as Ly6Chi CCR2+ inflammatory monocytes 
(Figure 4.1). 
Inflammatory monocytes were found to be present in circulation and increased as a 
proportion of total CD11b+ F4/80+ Ly6G- monocytes during disease progression 
(p<0.01)(Figure 4.1). The proportion of other CD11b+ Ly6G- monocytes decreased 
during tumour progression (p<0.01). B16F10 tumours were excised, washed and 
plated for 24hrs, tumours were confirmed to secrete CCL2 (>1000pg/ml/106 cells, data 








Figure 4.1 Circulating monocyte populations in subcutaneous B16F10 tumour bearing mice 
Mice were subcutaneously inoculated with B16F10 cells. At various points of tumour development 
blood was isolated and analysed by flow cytometry. Monocytes were gated according to forward scatter, 
side scatter and as CD11b+, F4/80+ and Ly6G-. a) Scatter plots of tumour size against the relative 
proportion of CCR2- Ly6Chi (left) CCR2- Ly6C+ (middle), and CCR2- Ly6C- (right) in the blood. b) 
Box plots of the data shown in (a) showing the proportion of cells when stratified between small 
(<0.5cm3) and large (>0.5cm3) tumours. Data shown is representative of n=6 per group. ** p<0.01 
***p<0.001 compared to small tumours. 
4.3.2 Development of BMDMs enriched for inflammatory monocyte-like cells 
In line with the three R’s of animal research, replacement, reduction and refinement, 
we next sought to develop monocytes in vitro from murine bone marrow which reflect 
the cells previously seen in vivo (Figure 4.1) [362]. Bone marrow was cultured in the 
presence of 50ng/ml M-CSF and analysed by flow cytometry daily to track their 
development (Figure 4.2). Monocytic cells were defined as CD11b+ CD115+ F4/80+ 
and with varying CCR2 and Ly6C expression [348]. Analysis of CD11b versus Ly6C 
allowed the identification of distinct monocyte subsets. 
The proportion of monocyte subsets varied between suspension and adherent 
populations, however once grouped on Ly6C and CD11b expression, other cell 
markers remained consistent indicating homogeneity of adherent and suspension 
populations, as such all cells were harvested for further use. 
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By day 5 non-monocytic CD11b- Ly6C- cells composed just 3 ± 1% of total cells. 
CD11b+ Ly6C+ cells were negative for CD115 and F4/80 (Figure 4.3) and are likely 
to represent an immature population of monocytic cells at a midway point to 
development, by day 5 however they represented a minimal proportion of the 
population at 10 ± 3%.  
CD11bhi Ly6C-, CD11bhi Ly6C+ and CD11b+ Ly6Chi populations were all positive for 
CD115 and F4/80 (Figure 4.3). F4/80 is a murine marker of monocytes which is 
present on monocytes and highly expressed on macrophages. CD11b+ Ly6Chi cells 
most accurately reflected inflammatory monocyte populations with CCR2 positivity 
and were Ly6G- (Figures 4.4-4.5).  These cells peaked in frequency at day 4, after 
which a gradual decline was seen from day 5 to day 7.  
In order to study the effect of tumour conditioning on peripheral monocytes infiltrating 
into the tumour, day 5 BMDMs were used which were comprised of 78 ± 3% CD11bhi 
Ly6C-cells, 3 ± 1% CD11bhi Ly6C-cells and 8 ± 0.07% inflammatory monocyte-like 
CD11b+ Ly6Chi cells. Thus monocytic subsets represented 89 ± 4% of cell populations 









Figure 4.2 The development of bone marrow derived monocytes 
Bone marrow was isolated and following RBC lysis was cultured in the presence of 50ng/ml M-CSF 
for between 2 and 7 days. a) Representative graphs showing CD11b and Ly6C expression of whole 
BMDM populations on day 2 (left) and day 5 (middle). b) Adherent only, suspension only and mixed 
populations were each analysed by flow cytometry from day 2 to day 7 to track the development of 
BMDMS. Populations shown correspond to the gating shown in (a). Data shown is representative of an 




Figure 4.3 CD115 and F4/80 expression of BMDM subpopulations 
Bone marrow was isolated and following RBC lysis was cultured in the presence of 50ng/ml M-CSF 
for 5 days. Shown are representative flow cytometry graphs showing the F4/80 and CD115 expression 
of the four monocytic populations identified in figure 4.2a, along with isotype control staining. 
 
Figure 4.4 CCR2 expression of BMDM subpopulations 
Bone marrow was isolated and following RBC lysis was cultured in the presence of 50ng/ml M-CSF 
for 5 days. a) Flow cytometry graphs showing the forward scatter and side scatter gating strategy used 
to gate BMDMs in figure 4.2. b) CCR2 expression of the four monocytic populations identified in 
figure 4.2a. c) Bar chart showing the mean CCR2 fluorescent intensity of the monocytic populations 





Figure 4.5 Ly6G expression of BMDM subpopulations 
Bone marrow was isolated and following RBC lysis was cultured in the presence of 50ng/ml M-CSF 
for 5 days. Shown are representative flow cytometry graphs showing the Ly6G expression of the four 
monocytic populations identified in figure 4.2a, along with isotype control staining. 
4.3.3 The effect of melanoma conditioning on BMDM surface markers 
To study the effect of tumour conditioning on monocytes we treated BMDMs with 
concentrated melanoma conditioned medium derived from B16F10 cells, termed B16 
conditioned medium (B16CM). As this contained a low level of serum, which has been 
shown to influence macrophage polarization, our no treatment negative controls were 
treated with an equivalent amount of ultracentrifuged medium with serum which was 
not exposed to B16F10 cells. To clarify this distinction we have labelled our no 
treatments as ‘no treatment concentrated medium’ (NTCM) [363]. Of note, FCS has 
been documented to contain varying cytokines, chemokines, growth factors and 
extracellular vesicles, all of which can influence macrophage polarization. To control 
for this the FCS for each experiment was derived from the same batch and the same 
stock solution.  
Treatments with either IFNγ and Lipopolysaccharide (LPS) or interleukin 4 (IL-4) and 
interleukin 13 (IL-13) were included as M1 and M2 controls, while their biological 
relevance is questionable, they have been included as assay positive controls and to 
give the results presented here context in comparison to other similar literature. 
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B16CM increased the expression of the ‘M2’ marker CD206 on CD11b+ cells, 
although not to the extent of IL-4 and IL-13 conditioned BMDMs (Figure 4.6a) [364]. 
B16CM was also shown to increase CD115 expression on CD11b+ cells to a similar 
extent as treatment with IL-4 and IL-13. 
To determine if this apparent ‘M2’-like shift was reflected in arginine metabolism 
which has been proposed as a central feature of the M1 M2 dichotomy, we determined 
the arginase activity of cell lysates and the secretion of nitrate species (Figure 4.6b-
c). B16CM increased arginase activity but was significantly lower than IL-4/IL-13 
treated BMDMs and comparable to IFNγ/LPS treated BMDMs. All populations fell 
below the detectable limit of nitrate detection indicating little or no iNOS activity in 
these cells, except for IFNγ/LPS treated BMDMs.  
Thus while B16CM treated BMDMs showed indication of an M2-like phenotype by 
CD206 and CD115 expression, supported by the absence of nitric oxide species 
secretion, the arginase activity was comparable to IFNγ/LPS treated M1-like BMDMs 









Figure 4.6 The effect of B16CM on the expression of CD206 and CD115 and activity of iNOS and 
Arginase by BMDMs 
BMDMs were treated on day 5 with NTCM, B16CM, IFNγ/LPS or IL-4/13 for 24hrs. a) Cells were 
analysed by flow cytometry to determine the level of CD206 expression or CD115 expression on 
CD11b+ BMDMs. b) Culture supernatants were analysed by Griess assay to determine the levels of 
iNOS activity c) Arginase activity was measured in cell lysates following treatment. Data was analysed 
using paired student’s t-tests. Data shown is representative of an n=3 per group. * p<0.05, ** p<0.01, 
*** p<0.001 compared to NTCM unless specified. 
4.3.4 The effect of melanoma conditioning on BMDM gene expression 
In order to determine the functional phenotype of these BMDMs we next evaluated 
the gene expression of BMDMs 4hrs and 24hrs following treatment.  
CD68 is a scavenger receptor expressed by monocytes and macrophages, which can 
be upregulated during activation [365]. In addition to the increase in surface markers 
CD206 and CD115 previously shown (Figure 4.6), gene expression of the surface 
markers, CD206 and CD68, were both shown to be increased by B16CM treatment 
after 4hrs and an increase in CD68 expression was still visible at 24hrs (Figure 4.7a).  
Analysis of ARG1 gene expression, the inducible form of arginase commonly seen in 
‘M2’ macrophages, and stained for in chapter 3, revealed no observable increase in 
expression and at 24hrs a significant decrease was observed (Figure 4.7b).  
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No change in IL-10, IL-12 or IL-6 expression was found after B16CM treatment. IL-
4/IL-13 treatment was shown to induce expression of TGFβ at 4hrs after treatment and 
IL-6 24hrs after treatment. IFNγ/LPS treatment showed no effect on TGFβ expression 
but increased IL-10, IL-12 and IL-6 expression 4hrs after treatment. The inflammatory 
genes IL-6 and IL-12 were still significantly increased 24hrs following treatment. 
Ym1 is a protein which has been linked to invasion. B16CM treatment was shown to 
reduce Ym1 expression after 24hrs and was significantly lower than IL-4 and IL-13 
treated BMDMs and IFNγ/LPS treated BMDMs after 4hrs. 
Thus, while B16CM was shown to impact surface marker expression by flow 
cytometry and qPCR, there was very little change in the expression of functional 








Figure 4.7 The effect of B16CM on gene expression of BMDMs 
BMDMs were treated on day 5 with NTCM, B16CM, IFNγ/LPS or IL-4/13 for 4 or 24hrs. Total RNA 
was isolated and analysed for relative gene expression by qPCR. Results were normalized to NTCM 
only. a) Gene expression for the surface receptors CD206 and CD68 was measured following treatment. 
b) Gene expression of the functional proteins ARG1, TGFβ, IL-10, IL-12, IL-6 and Ym1 was measured 
following treatment. Data shown is representative of an n=3 per group. Data was analysed using paired 
student’s t-tests. * p<0.05, ** p<0.01, *** p<0.001 compared to NTCM (a mean value of 1 in all graphs 
due to normalization of data) unless specified. 
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4.3.5 The effect of melanoma conditioned BMDMs on CD4+ T cell responses  
To determine if the limited functional capacity seen in gene expression would translate 
to a reduced influence in determining tumour immunology we next sought to identify 
the effect of B16CM treated BMDMs on CD4+ T cell activity (Figure 4.8).  
NTCM treated BMDMs were able to induce the proliferation of CD4+ T cells, to a 
similar level as IL-4/IL-13 treated BMDMs, however B16CM treated BMDMs 
significantly decreased the proportion of activated T cells.  
Analysis of culture supernatants showed NTCM, B16CM and IFNγ/LPS treated 
BMDMs failed to generate IL-4 secretion by CD4+ T cells, however IL-4/IL-13 treated 
BMDMs resulted in a significant increase in IL-4 secretion. 
While macrophages were able to directly secrete IFNγ (shown in grey, Figure 4.8d, 
p<0.05), coculture revealed significant additional IFNγ secretion from CD4+ T cells 
across all conditions. B16CM treated BMDMs significantly increased secretion of 
IFNγ compared to NTCM and IL-4/13 treated BMDMs but not to the extent of 
IFNγ/LPS treated cells. 
Flow cytometric analysis of activated CD4+ T cells showed the induction of CXCR3 
and CD25 on CD4+ T cells by NTCM treated BMDMs. B16CM treated cells resulted 
in a decrease of CXCR3+ T cells but had no effect on the number of CD25+ T cells. 
Both IFNγ/LPS and IL-4/IL-13 treated BMDM cocultures resulted in significantly 
lower numbers of CD25+ and CXCR3+ T cells compared to NTCM treated cells. The 
trend indicated they were also lower than T cells cocultured with B16CM treated cells, 
however this trend was only significant for the expression of CXCR3 T cells 
cocultured with IFNγ/LPS treated BMDMs. 
While B16CM treated BMDMs reduced CD4+ T cell proliferation and the level of 
activated T cells positive for the Th1 marker CXCR3, they also increased IFNγ 
secretion which is central to driving Th1 type anti-cancer immune responses. To 
further investigate the effect on the anti-tumour immune response we investigated the 




Figure 4.8 The effect of treated BMDMs on CD4+ T cell expansion and polarization 
Day 5 BMDMs were treated for 24hrs. Following treatment the cells were washed twice and cocultured 
with freshly isolated CFSE labelled splenic CD4+ T cells from syngeneic mice for 7 days. Cells were 
analysed by flow cytometry and supernatants were analysed by ELISA. a) T cells were gated for by 
CD4 expression. Shown are representative graphs of CXCR3 against CD25 for each of the treatment 
groups. b). CD4+ T cell proliferation was determined by reduced CFSE staining. c) Bar charts showing 
the number of CD25+ and CXCR3+ CD4+ T cells determined using the gating shown in (a). d) Shown 
in white bar charts are the IL-4 and IFNγ levels in supernatants following coculture, overlaid in grey 
are the level of the same cytokines following culture of treated BMDMs alone. Data shown is 
representative of an n=3 per group. Data was analysed using paired student’s t-tests * p<0.05, ** 











4.3.6 The effect of melanoma conditioned BMDMs on CD8+ T cell responses  
To determine if B16CM treated BMDMs could have an effect on cytotoxic CD8+ T 
cell behaviour we examined the proliferation of CD8+ T cells cocultured with treated 
BMDMs. 
B16CM treated BMDMs were shown to significantly increase the proliferation of 
CD8+ T cells in comparison to NTCM, IFNγ/LPS and IL-4/13 treated cells. IFNγ/LPS 
and IL-4/13 treated cells had no significant impact on CD8+ T cell expansion (Figure 
4.9). 
Along with increased CD8+ T cell proliferation, B16CM treated BMDMs were found 
to increase the granzyme B levels of CD8+ T cells. This increase was above the level 
seen following coculture with either IFNγ/LPS or IL-4/13 treated BMDMs indicating 
that B16CM treated BMDMs may prime CD8+ T cells for cytotoxic responses. 
All BMDMs were found to stimulate secretion of IFNγ by CD8+ T cells. B16CM 
significantly increased IFNγ secretion, and this was also significantly higher than that 
induced by IL-4/IL-13 treated BMDMs, but was over 10 fold less than IFNγ secreted 
by cells cocultured with IFNγ/LPS treated BMDMs.  
Although B16CM treated BMDMs in coculture significantly increased IL-10 levels 
compared to T cells alone this was lower than the levels seen by B16CM treated 
BMDMs alone in culture. This trend was seen in cocultures with all BMDM treatments 
except for cocultures with IFNγ/LPS treated BMDMs which were significantly higher 
following inclusion of T cells (p<0.01) indicating CD8+ T cell secretion of IL-10 is 




Figure 4.9 The effect of treated BMDMs on CD8+ T cell expansion and polarization 
Day 5 BMDMs were treated for 24hrs. Following treatment, BMDMs were washed twice and 
cocultured with freshly isolated CFSE labelled splenic CD8+ T cells from syngeneic mice. Cells were 
incubated for 5 days. a) CD8+ T cell proliferation was determined by reduced CFSE staining. b) 
Granzyme B levels were determined by flow cytometry. c-d) Shown in white bar charts are the IFNγ 
and IL-10 levels in supernatants following coculture, overlaid in grey are the level of the same cytokines 
following culture of treated macrophages alone. Data shown is representative of an n=3 per group. Data 









It has been noted that M-CSF derived BMDMs adopt an M2-like phenotype. This 
polarization phenomenon cannot be avoided with the use of BMDMs derived from M-
CSF of GM-CSF (GM-CSF derived cells conversely adopt a relative M1-like 
phenotype and the inclusion of a dendritic cell population). Many protocols involve 
the culturing of cells for 7-14 days, however it is likely that this may be subversive in 
dissecting the minutiae of monocyte/macrophage function, as it often requires 
powerful signalling to see any shift away from an M-CSF induced M2-like phenotype. 
Other studies have used M-CSF withdrawal or GM-CSF pulsing prior to stimulation 
to induce a ‘M0’ phenotype prior to activation, however all starting states are 
subjective to the protocol used and the results presented should be noted in that 
context. To aid reproducibility we have retained a simplified protocol but future work 
is required to determine if the results presented can be recapitulated under different 
BMDM culturing conditions [24].  
Due to the leaky vasculature of tumour tissue it was traditionally presumed that 
peripheral circulating monocytes were readily trafficked the tumour 
microenvironment. However, it has been shown in a murine model of colon adenoma 
that the tumour may contain a dominant population of self-maintaining macrophages 
distinct from circulating populations [366]. However, using a subcutaneous B16F10 
model of murine melanoma which secretes CCL2 we have shown that the levels of 
circulating CCR2+ inflammatory monocytes increases during tumour progression. 
Using the B16 cell line variant B16BL6 tumour model, it has been shown that the level 
of monocytic proliferation in the tumour is low and that bone marrow is likely to 
provide a continuous flow of poorly proliferating monocytes to the tumour [367].  A 
recent paper has also shown that circulating inflammatory monocyte levels correlate 
to both intratumoural macrophage infiltration and patient survival in colorectal cancer 
[329]. 
In order to form an in vitro model to study the effect of B16F10 tumours on these cells 
we opted to treat M-CSF derived BMDMs on day 5 with conditioned medium. This 
population, which is 89 ± 4% mature monocytic cells, is enriched for inflammatory 
monocyte-like cells and limits the M2 polarizing effect of M-CSF itself. 
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The model contains inherent limitations including the purity of the cell population and 
also the effect of tumour conditioning is effected by  B16F10 secreted factors only and 
does not account for any cell-cell interactions or biochemical effects such as hypoxia 
or low pH commonly exerted in the TME.  
Due to limited availability of clinical tissue, the function of TAMs is often inferred 
from surface markers commonly expressed by M2-like cells seen during examination 
of formalin fixed paraffin embedded tissue [310]. 
Here we have shown that expression of cell surface markers traditionally associated 
with ‘M2’ macrophages, may not reflect functional activity and these cells expressing 
‘M2’ markers may instead promote anti-cancer immune responses via CD8+ T cell 
expansion, IFNγ expression and increased cytotoxicity. B16CM increased the 
expression of cell surface markers CD206, CD115 and CD68 but this did not translate 
into a change in IL-10 or IFNγ production as determined by ELISA or IL-6, IL-10, IL-
12 or TGFβ expression as determine by qPCR. These results reflect previous studies 
showing that B16F10 conditioned medium can inhibit cytokine production by murine 
lymphocytic preparations and that melanoma derived exosomes can promote mixed 
M1 M2 polarization in macrophages, although melanoma derived exosomes were able 
to augment the production of cytokines such as TNFα, IL-1β and IL-10 [368,327]. 
TGF-β can be secreted by M2-like macrophages and can promote tumour cell 
stemness and migration while both TGF-β and IL-10 are potent inhibitors of effective 
T cell responses [369,370]. A reduction in these immunosuppressive mediators is 
positive in an anti-cancer context but the inability of B16CM treated BMDMs to 
produce IL-6 or IL-12 which are both potent inflammatory mediators required for the 
induction of IFNγ secreting T cells indicates a more ambiguous role in disease [371].  
Coculture with T cells showed a marginal decrease in CD4+ T cell expansion by 
B16CM treated BMDMs but an increase in CD8+ T cell expansion. Coculture of 
B16CM treated BMDMs with either CD4+ or CD8+ coculture also increased IFNγ 
secretion by T cells, which has been identified as a central cytokine in driving anti-
cancer Th1 immune responses.  
These results are in contrast to other studies which have shown that direct treatment 
of T cells with cell line conditioned medium or fractionated exosomes from 
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conditioned medium reduces T cell proliferation and induces a suppressive CD8+ T 
cell phenotype [372].  
Intratumoural depletion of Tregs has been shown to control the growth of murine 
models of melanoma as these cells can inhibit the cytotoxic anti-tumour effect of CD8+ 
T cells [373,374]. Tregs have also been shown to correlate to prognosis in human 
melanoma indicating that they play an influential role in disease [375-377]. There is 
intimate cross talk between melanoma derived factors, including melanoma derived 
exosomes and cytokines, and T cells that can affect their function 
[378,295,373,296,379]. The ability of B16CM treated BMDMs to induce CD8+ T cell 
proliferation and cytotoxicity without increasing the frequency of CD25+ T cells may 
indicate that these cells could counteract the direct inhibitory effect of conditioned 
medium on T cells. 
Similar factors such as cytokines and exosomes are present in FCS, and while 
controlled for in this study, serum free growth media are becoming increasingly 
available and may permit more sensitive studies to be performed on the effect of cell 
line conditioned media or their constituents. 
Due to their role in a wide range of tumour promoting activities, macrophages have 
been viewed as actionable targets in the development of novel anti-cancer 
therapeutics, however these efforts have been largely unsuccessful. Understanding the 
role of TAMs is essential for the development of effective therapeutics, these results 
suggest that the presence of M2 markers on macrophages, as are commonly reported 




































Electroporation in combination with chemotherapy is an established treatment used on 
solid malignancies that results in enhanced chemotherapeutic uptake. Recent advances 
have begun to transition to the use of non-toxic compounds in lieu of chemotherapy, 
death, such as calcium which can also induce tumour cell death. While the effect of 
treatment on tumour cell death has been well characterized and has been shown to 
induce an immunogenic form of cell death, the effect of treatment on intratumoural 
immune cells has not been investigated. Here we present the first study showing the 
effect of tumour electroporation on immune cells, using melanoma-conditioned 
BMDMs. Similar to tumour cells, macrophage cell membranes are susceptible to 
poration following pulsing and subsequently reseal. Melanoma conditioned BMDMs 
are resistant to calcium electroporation induced cell death in comparison to B16F10 
melanoma cells. However treatment with electroporation with or without bleomycin 
or calcium was shown to affect macrophage phenotype and function. Coculture of 
calcium electroporated macrophages revealed that both the capacity of macrophages 
















EP is a local treatment application which can be used to form transient pores in the 
cell membrane. Electrodes are placed in direct proximity to the tissue of interest and 
a series of pulses are delivered which exceed the dielectric potential of the cell 
membrane resulting in the formation of pores which can persist for several seconds to 
several minutes before resealing and leaving cells intact and viable.  
EP has been used in a cancer context to increase the uptake of chemotherapeutics, 
especially hydrophobic drugs, such as bleomycin, which can have poor rates of passive 
cell penetration. However, EP has also been used in combination with non-toxic drugs 
such as calcium, which when delivered in sufficient concentrations can induce rapid 
cell death [225]. Due to variations in tissue resistance and conductivity, EP can be 
safely used in proximity to healthy tissue and vasculature, making it an attractive 
alternative in a range of tumour types. 
EP with chemotherapy, termed ECT, is routinely used for the treatment of dermal 
lesions but endoscopic devices have been designed for the treatment of oesophageal 
and colorectal cancers. Other devices are currently in development to facilitate EP of 
other organ sites. Complete response rates in excess of 80% have regularly been 
reported for treatment of dermal lesions with ECT.  
ECT with bleomycin has been shown to induce an immunogenic form of cell death 
characterized by enhanced ecto-calreticulin and adenosine triphosphate (ATP) and 
high-mobility group protein 1 (HMGB1) release by treated cells. An influx of immune 
cells is also seen following treatment, including macrophages, indicating that ECT 
may be utilized to induce an anti-cancer immune response [380]. However, while ECT 
has been shown to repress distal tumour growth in murine models, this is not seen in 
clinically advanced cancer patients [380]. 
The substitution of chemotherapy with calcium was rationally designed in part due to 
the hypothesized immunogenic effects of calcium uptake, and to abrogate the 
immunosuppressive effects of chemotherapy. Promisingly, a case study in malignant 
melanoma treated with calcium EP in combination with ECT has reported remission 
of both local treated and distal untreated tumours, indicating a systemic anti-cancer 
immune response or other abscopal effect [225]. 
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Due to the immunogenic potential of EP treatments, the effect of treatment in 
combination with other immunogenic modalities, including T cell check point 
inhibitors, is under investigation [381,382]. However the direct effect of EP on 
intratumoural immune cells is not known. Here, using a BMDM model of melanoma 
TAMs, we show for the first time that EP can induce reversible pore formation on 
macrophages that can impact their size, viability, phenotype, function and role in T 





















5.3.1 Optimization of B16F10 electroporation parameters 
As electrical parameters of tumour EP are optimized to induce tumour cell death, we 
first optimized the in vitro delivery of EP on B16F10 tumour cells. Cell poration was 
measured in parallel with the subsequent viability of cells 30min following EP (Figure 
5.1a). At 800V/cm the sum of non-viable cells and porated cells surpassed 100%, 
indicating that a proportion of electroporated cells did not regain membrane integrity. 
As such 700V/cm was selected as an appropriate voltage to induce reversible EP in 
B16F10 cells. 
Using this voltage preliminary data was generated to ensure cell viability at 24, 48, 
and 72hrs post treatment (Figure 5.1b). Using previously optimised concentrations of 
bleomycin (10nM) and calcium (0.5-5mM) we examined the nature of cell death 
following treatment. No loss in viability was observed following EP. A daily increase 
in viability was observed however this was considered likely to be an artefact of 
experimental technique, in which B16F10 cells do not respond optimally to repeated 
trypsinisations within short periods and the nature of the EP buffer used. 
Significantly decreased viability was seen in cells treated with bleomycin ECT 3 days 
post treatment compared to EP only (p<0.01) and in contrast a significant decrease 
was seen in 24hrs post treatment in cells treated with calcium EP (p<0.001). This 
reduction in viability which was no longer apparent at 48 or 72hrs indicates that cells 
not killed by treatment are able to recover following treatment. As expected these 









Figure 5.1 Optimisation of electroporation parameters in B16F10 cells 
a) B16F10 cells were electroporated at a range of voltages, cell poration was measured by PI uptake 
during EP and cell viability was determined by PI uptake 30min following electroporation. b) Cells 
were electroporated at 700V/cm with or without drug and were analysed for viability 24, 48 and 72hrs 
post treatment. Data was analysed using paired student’s t-tests. Data shown is representative of an n=3 
per group. * p<0.05, ** p<0.01, *** p<0.001 compared to NT at the same time point unless specified. 
No Treatment (NT) 
5.3.2 Loss of B16F10 cell viability following Ep with calcium or bleomycin 
To further determine the nature of cell death following treatment, we performed serial 
matched viability analysis on B16F10 cells following calcium EP at a range of calcium 
concentrations (Figure 5.2a-d). No cell death was observed in cells treated with 
500μM calcium, indicating doses of 2.5mM or greater are required to generate 
therapeutic cell death in a B16F10 model of melanoma. A significant drop in viability 
was seen in cells treated with 2.5mM calcium or higher in combination with EP, which 
had occurred by 30min post treatment. The level of cell death continued to increase 
for 6hrs, but an increase in viability was seen in all conditions by 8hrs after treatment. 
The doubling time of B16F10 cells is approximately 15hrs, so improved viability is 
likely a result of replication by intact cells rather than the recovery of cells which had 
lost membrane integrity for up to 6hrs. For further studies we chose to use 500μM as 
a low ineffective dose and 5mM as the upper dose as rates of cell death between 5 and 
10mM were non-significant.  
To determine if cells not acutely killed following calcium EP had any loss in malignant 
potential, we performed clonogenic assays on cells which were viable 24hrs following 
treatment (Figure 5.2e). No change was seen in clonogenic ability, indicating that 
cells not killed acutely have normal replicative potential. 
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Conversely, we performed clonogenics with viable cells selected 24hrs following EP 
with bleomycin (Figure 5.2f). No colonies were established in comparison to all 
controls (p<0.001), indicating all cells were killed by treatment. These results are in 
agreement with previous literature indicating that electrochemotherapy results in cell 




Figure 5.2 Cell death following electroporation with bleomycin or calcium 
B16F10 cells were electroporated at 700V/cm with or without drug. a-d) Serial matched measurements 
of cell viability were taken following calcium EP. e-f) Viable cells were isolated 24hrs post treatment 
by selection of adherent cells and seeded at a low concentration for clonogenic analysis. Data was 
analysed using paired student’s t-tests. Data shown is representative of an n=3 per group (a-d and f) and 








5.3.3 Poration of BMDMs following EP with or without calcium 
Using the above optimised parameters melanoma conditioned BMDMs were 
electroporated. The efficiency of EP in the presence of calcium was also investigated 
as extracellular calcium is known to affect membrane resealing and other membrane 
dynamics through its role in voltage generation (Figure 5.3a) [383]. EP induced cell 
poration in 64.26% ±4.64% of BMDMs, which was unchanged by the addition of 
calcium (Figure 5.3b).  
Although calcium did not affect the level of porated cells, there was a shift in cell size 
following EP with calcium, with calcium EP resulting in phenotypically smaller cells 
as determined by forward scatter (p<0.001) (Figure 5.3a and 5.3c). This effect was 
induced by both 5mM calcium and the lower dose 500μM which was non-lethal in 
B16F10 cells. 
 
Figure 5.3 Electroporation of melanoma conditioned BMDMs 
Melanoma conditioned BMDMs were electroporated at the same parameters as were used for B16F10 
cells. a-b) Poration was measured by PI uptake during EP. Total number of porated cells were calculated 
by addition of the PI+ FCSlo and PI+ FCShi gates from (a).  c) Cell size was determine by flow cytometric 
forward scatter readings, graphed is the MFI of PI+ FCSlo and PI+ FCShi events from (a). Data was 
analysed using paired student’s t-tests. Data shown is representative of an n=3 per group. *** p<0.001 






5.3.4 Effect of EP with calcium or bleomycin on BMDM viability 
Following determination that BMDMs are porated we next analysed the viability of 
cells following treatment with EP with or without calcium or bleomycin (Figure 5.4). 
As BMDMs have limited replicative potential the effect of therapy was followed for 
up to 5 days. At 1hr post treatment, all cells except those treated with EP with 5mM 
calcium (p<0.05) were as viable as untreated cells (Figure 5.4a). These results 
indicate that following poration, in which over 60% of cells are porated, cells regain 
membrane integrity.  
At 24hrs post treatment, cells treated with EP with or without bleomycin displayed a 
marked reduction in viability, indicating an EP related toxicity in BMDMs (Figure 
5.4b). This is likely due to sensitivity to the composition of their cytoplasmic contents 
which can be distorted by loss of cytoplasm and gain of extracellular medium during 
treatment. 500μM calcium was protective to electroporated cells, resulting in 
significantly reduced death compared to EP alone (p<0.05). There was no significant 
difference between 500μM calcium EP and non-treated cells although there was a 
slight trend of decreased viability. This protective role of calcium was lost in the 
presence of 5mM calcium (p=0.0678). Thus low levels of calcium are most protective 
for conditioned BMDMs following treatment.  
At 5 days post treatment the decrease in viability of electroporated cells was less 
pronounced but still present (p<0.01) (Figure 5.4c). The addition of bleomycin 
decreased the viability of non-treated and electroporated cells, however bleomycin 
induced a larger level of cell death in combination with EP compared to passive 
exposure (29.95±13.45% vs 45.89±16.12%, p=0.0642). Both doses of calcium proved 
protective at 5 days post treatment, with no significant change from non-treated or 






Figure 5.4 Viability of melanoma conditioned BMDMs following electroporation with bleomycin 
or calcium 
Melanoma conditioned BMDMs were electroporated in the presence of bleomycin or calcium. Viability 
was determined by PI uptake at 1hr (a), 1 day (b) and 5 days (c) post treatment. Data was analysed using 
paired student’s t-tests. Data shown is representative of an n=7 per group. * p<0.05, ** p<0.01, *** 


















5.3.5 Effect of EP with calcium or bleomycin on BMDM surface markers and 
arginase activity 
Following confirmation that some BMDMs can survive EP, we next sough to 
phenotype cells to determine any shifts in behaviour. Cells were isolated 72hrs post 
treatment and the canonical M1:M2 enzymes, iNOS and arginase, were assayed in 
combination with cell surface markers. Viable CD11b+ BMDMs can be separated in a 
binary fashion into F4/80+ CD115- or F4/80hi CD115+ cells. An upregulation of F4/80 
accompanied with CD115 induction is indicative in murine myeloid cells of a 
transition from monocyte to macrophage [285]. The linear evolution of these cells is 
poorly understood, however this shift is commonly associated with an upregulation of 
M2-like behaviour [348]. EP resulted in a significant decrease in this maturation 
process (Figure 5.5a), which was maintained in cells treated with bleomycin EP. 
However the addition of calcium, in a dose dependent manner, reduced this decrease 
(p<0.001). The M2-like phenotype of these matured cells was reflected by the CD206 
expression of CD11b+ cells (Figure 5.5b). 
All cells assayed were negative for detectable nitrates in supernatant using Griess 
assay (data not shown). While EP induced a decrease in F4/80hi CD115+ cells, there 
was no change in arginase activity in these cells (Figure 5.5c).  And despite a relative 
increase in F4/80hi CD115+ in cells treated with calcium EP, these cells displayed 
marked reduction in arginase activity, that was independent of EP, indicating that 








Figure 5.5 Phenotypic evaluation of melanoma conditioned BMDMs following electroporation 
with bleomycin or calcium 
Melanoma conditioned BMDMs were electroporated in the presence of bleomycin or calcium and 
cultured for 72hrs. a-b) Cells were analysed by flow cytometry for macrophage activation markers. 
BMDMs were identified as CD11b+ (Figure 2.5) and gated according to F4/80, CD115 and CD206 
expression. c) Intracellular arginase activity was assayed following cell lysis. Data was analysed using 
paired student’s t-tests. Data shown is representative of an n=3 per group. * p<0.05, ** p<0.01, *** 

















5.3.6 Effect of calcium electroporation of BMDMs on subsequent CD4+ T cell 
activation 
Due to enhanced survival of cells treated with calcium EP, and increased maturation 
coupled with decreased arginase activity this treatment was selected as the most 
promising for further immunological studies. The effect of treated BMDMs on CD4+ 
T cells was determined by coculture experiments using BMDMs isolated 24hrs after 
treatment in combination with freshly isolated splenic CD4+ T cells. 
Calcium EP of BMDMs was found to decrease their ability to stimulate CD4+ T cell 
proliferation compared to BMDMs treated with EP only (Figure 5.6a). Cells treated 
with or without EP resulted in no detectable IL-10 in supernatant (Figure 5.6c), 
however calcium treatment induced IL-10 secretion. This effect was further increased 
by 5mM calcium in combination with EP (p<0.05). IFNγ secretion patterns inversely 
reflected IL-10 expression (Figure 5.6d). EP alone induced high levels, and the 
addition of calcium reduced IFNγ secretion. These results suggest that while EP alone 
may promote relative Th1 responses, calcium EP shifts this towards a Treg response. 
This is also reflected by the Th2 cytokine IL-4, which often accompanies Treg 
responses, and which was detectable in trace amounts following treatment with 
calcium EP (Figure 5.6b). 
A decrease in IFNγ was reflected by decreased CXCR3 expression on activated T cells 
(Figure 5.6f) following calcium EP. There was a decrease also in the Treg marker, 
CD25, following calcium EP (p<0.01), however CD25 expression is also coupled to 
T cell activation and could reflect decreased activation as is mirrored in the reduced T 




Figure 5.6 Effect of melanoma conditioned BMDMs following electroporation on CD4+ T cells 
Melanoma conditioned BMDMs were electroporated in the presence of bleomycin or calcium and 
cultured for 24hrs. Cells were then cocultured with freshly isolated CFSE labelled CD4+ T cells. T cell 
proliferation was measured by reduced CFSE expression (a). Levels of IL-4 (b), IL-10 (c) and IFNγ (d) 
in the supernatant were measured by ELISA. Activated T cells were gated by low CFSE expression and 
CD25 (e) and CXCR3 (f) expression was determined by flow cytometry. Data was analysed using 
paired student’s t-tests. Data shown is representative of an n=3 per group. * p<0.05, ** p<0.01, *** 




5.3.7 Effect of calcium electroporation of BMDMs on subsequent CD8+ T cell 
activation 
To fully elucidate the role of electroporated macrophages in anti-cancer immunity we 
subsequently examined the effect of treated BMDMs on cytotoxic CD8+ T cell 
responses.  In contrast to CD4+ T cell activation, calcium EP was shown to increase 
the CD8+ T cell activation potential of melanoma conditioned BMDMs, as seen by a 
reduction in CFSE mean fluorescent intensity (MFI) (Figure 5.7a). EP of BMDMs 
had no effect on subsequent CD8+ T cell proliferation, however calcium treatment 
increased activation in an apparently dose dependent manner (p=0.0892). Intracellular 
granzyme B was detectable in both BMDMs and CD8+ T cells (Figure 5.7b-c).  
BMDM calcium treatment resulted in an increase in granzyme B in both BMDMs and 
cocultured CD8+ T cells. EP decreased BMDM granzyme B levels (p<0.05), which 
was also evident in decreased BMDM granzyme B levels in 500μM calcium EP (non-
significant) and 5mM calcium EP (p=0.05) compared to respective passive treatments. 
BMDM EP had no effect on CD8+ T cell granzyme B levels across any of the tested 
conditions compared to respective passive treatments. Passive exposure of BMDMs 
to calcium increased the granzyme B levels of cocultured CD8+ T cells. 
 Secretion of IL-10 and IFNγ were also measured as CD8+ T cells are significant 
sources of both IL-10 and IFNγ in vivo (Figure 5.7d-e).  Similarly to CD4+ T cell 
coculture, passive calcium treatment induced a dose dependent increase in IL-10 
levels, which was independently of EP, however calcium levels were of a 4 to 6 fold 
lower concentration than from CD4+ T cell cocultures. No changes were observed in 
IFNγ secretion levels except by cocultures with BMDMs treated with 5mM EP  in 




Figure 5.7 Effect of melanoma conditioned BMDMs following electroporation on CD8+ T cells 
Melanoma conditioned BMDMs were electroporated in the presence of bleomycin or calcium and 
cultured for 24hrs. Cells were then cocultured with freshly isolated CFSE labelled CD8+ T cells. T cell 
proliferation was measured by reduced CFSE expression (a). Intracellular levels of granzyme B were 
determined by flow cytometry in treated BMDMs (b) and cocultured activated CD8+ T cells. Levels of 
IL-10 (d) and IFNγ (e) in the supernatant were measured by ELISA. Data was analysed using paired 
student’s t-tests. Data shown is representative of an n=3 per group. * p<0.05, ** p<0.01, *** p<0.001 






ECT is a well-established treatment modality with high complete response rates. The 
EP pulses are optimized to result in reversible cell poration with minimal ablative 
effects [384,385]. The cytotoxic effects of ECT are manifested by intracellular 
bleomycin during cell proliferation following treatment, as supported by the cell death 
shown (Figure 5.5) [385]. Despite promising indications, calcium EP is not yet well 
established and is currently restricted to use on an investigative basis.  
The fundamental mechanism of cell death following calcium EP is different to ECT 
as no chemotherapeutic is present. It has previously been suggested that calcium EP 
results in necrotic cell death as a result of severe ATP depletion [386]. In agreement 
with this, here we have shown that the cell death following treatment is acute, in which 
cells do not regain membrane integrity or lose viability within 6hrs of treatment 
(Figure 5.5). Cells which survive this initial insult show no loss of proliferative 
potential.  
Having successfully generated these treatment models in a melanoma cell line, we 
subsequently examined the effect of these electroporation parameters on syngenic 
BMDMs treated with B16F10 conditioned medium to mimic melanoma conditioning. 
These cells were shown to be susceptible to EP and regained membrane integrity 
following treatment. However, EP resulted in a subsequent reduction in viability at 
24hrs which was still evident 5 days following treatment. In tandem with this effect 
was a selective depletion of CD115+ F4/80hi and CD206+ cells. CD115+ F4/80hi and 
CD206+ are macrophage-like cells and also M2-like, in contrast to CD115- F4/80mid 
cells which are monocyte-like and M1-like. It is commonly considered that M2-like 
cells can support tumour growth and inhibit anti-cancer T cell responses while M1-
like cells can exert inflammatory responses that can support anti-cancer immune 
responses [387-389]. While CD115+ F4/80hi cells were depleted by EP, cell 
populations retained their arginase activity, indicating the retention an M2-like 
phenotype. EP alone of BMDMs showed no subsequent effect on T cell proliferation 
or polarization as determined by surface markers but did result in increased IFNγ 
secretion in CD4+ T cell cocultures. 
ECT did not induce any further cell death in comparison to EP alone in the first 24hrs 
(Figure 5.7). By day 5 there is a further reduction in viability caused by ECT beyond 
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the loss of viability seen with EP alone (p<0.01). In a tumour context, there is a 
continual supply of TAMs from circulating monocytes and while it has been shown 
that some murine models contain populations of self-maintaining macrophage 
populations, it is likely that a continuous supply from the circulation is the 
predominant source of TAMs [185,390,366,391]. Therefore, while it is likely to effect 
coculture behaviour, it cannot be speculated whether viability declines seen after the 
first 24hrs will have a meaningful effect on in vivo macrophage tumour biology. ECT 
followed the same trend of CD115+ F4/80hi and CD206+ depletion as EP but did non-
significantly decrease arginase activity indicating that ECT may impair M2-like 
responses. 
Calcium EP of melanoma conditioned BMDMs displayed a remarkably different 
response profile compared to EP alone. Immediately following treatment cell size was 
significantly reduced. Following treatment an initial loss in viability was seen in cells 
treated with 5mM calcium EP, however the scale of cell death in comparison to 
B16F10 cells was markedly reduced. At 1hr following treatment with 5mM calcium 
there was a reduction of viability of 73.26±3.28% of cells in B16F10 cells compared 
to only 22.62±7.42% in melanoma conditioned BMDMs (p<0.01 difference in means). 
By 24hrs calcium had played a protective role in improving viability following EP, 
and by day 5 no significant difference was observable between untreated cells and 
cells treated with calcium EP. 
Calcium is known to influence a variety of signalling pathways, and among other 
pathways is coupled to purinergic receptor signalling in macrophages, which are 
known to regulate migration and activation [392]. Thus it is intuitive that calcium 
treatment will induce phenotypic and functional changes in treated macrophages. 
Calcium EP diminishes the reduction of F4/80hi CD115+ cells seen following EP 
despite the initial phenotypic shift towards cell shrinking, but instead of increasing 
arginase expression associated with these cells, there is a down regulation of arginase 
activity. This effect, with lower (500μM) doses is independent of EP, indicating that 
passive calcium treatment can impart lasting effects on BMDMs.  Mirroring this 
effect, calcium treatment of BMDMs in the absence of EP affected subsequent CD8+ 
T cell proliferation and both CD4+ and CD8+ T polarization and activation. 
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Cells were washed following treatment 3 times, negating the possibility of prolonged 
exposure to EP buffer or calcium treatments. However calcium is known to interact 
with and affect the plasma membrane. Providing a hypothesis for the effects of 
calcium seen in the absence of EP, such as decrease arginase activity. 
The interaction of calcium with the plasma membrane is poorly understood but has 
been shown to be both complex and specific [393]. Calcium can interact with the 
phosphate groups of phosphatidylcholine which can constitute 40-80% of the plasma 
membrane and can affect lipid clustering which has been shown, among other process 
to control T cell activation, and is known to affect macrophage intracellular signalling 
[394-396]. Extracellular calcium depletion has also been shown to reduce macrophage 
phagocytosis and cytokine secretion, and the influx of calcium is coupled to signalling 
via TRPV2 [397-399]. Thus the effect of passive exposure to calcium resulting in 
functional differences is not anomalous with previous results, however physiological 
extracellular calcium concentrations are approximately 2mM while culture media 
range from 0.7-1.7mM, indicating that the effect observed may equally be due to the 
temporary removal of extracellular calcium in negative controls while in calcium free 
EP buffers during experiments [399]. 
Over active ATPase activity by cells attempting to regain homeostatic intracellular 
calcium concentrations has been hypothesized as a potential cause of severe ATP 
depletion following calcium EP [400,401]. However it is possible that calcium free 
buffers result in cytoplasmic calcium depletion which is also energetically taxing on 
cells.  Further research is required to determine if low levels of calcium in EP buffers 
can reduce energetic stress on cells following treatment. 
That calcium EP can upregulate IL-10 secretion from both CD4+ and CD8+ T cell 
cocultures in a dose dependent manner indicates that high dose calcium administration 
may inhibit anti-cancer immune responses as directed by exposed macrophages. 
However they exert complex effects, also increasing CD8+ T cell proliferation and 
granzyme B levels in activated T cells indicating the expansion of cytotoxic immune 
responses in a dose dependent manner. Most strikingly, CD8+ T cell cocultures with 
BMDMs treated with high dose (5mM) calcium electroporation were the only 
treatment which displayed an increase in IFNγ. IFNγ is a potent activator of Th1 anti-
cancer immune responses.  
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When administered in combination with EP, calcium dosage can affect the level of 
tumour cell death [402,403]. From this data, it is clear melanoma conditioned BMDMs 
are susceptible to poration by EP but relatively resistant to calcium EP induced cell 
death. However exposed cells are phenotypically and functionally altered.  To our 
knowledge, this is the first study examining the effect of EP, as designed for the 
treatment of solid tumours, on immune cells which are also exposed to treatment. In 
vivo investigation is required to see if the increase in cytotoxic CD8+ T cell activity 
will be seen in a disease setting. Further investigation of other immune cell types, is 
required to determine if immune responses are compromised, and if therapeutic 
administration can be optimized to balance immunogenic tumour cell death with the 
















































It is known that tumours can polarize macrophages to an M2-like phenotype through 
a variety of mechanisms, including hypoxia, lactate, and immunosuppressive 
cytokines [404-406,369]. We have shown that human melanoma tumours contain 
distinct macrophage populations with different biological activity and a predominance 
of CD163+ M2-like TAMs in the TME and peritumoural tissue. Thus the high level of 
CD163+ macrophages seen in the TME is in line with expected observations. Our 
results are also in alignment with the hypothesis that M2 macrophages accumulate 
during the course of disease, although we cannot offer a mechanism, others have 
speculated that this is reflective of an continual influx of monocyte-derived 
macrophages which are then polarized to an M2-like phenotype in the TME, and 
which is supported by numerous in vitro and preclinical studies [250,407-410].  
In contrast, a much smaller population of CD68+ macrophages exist in and around 
some human melanoma tumours, but not in all cases. These may reflect recently 
recruited monocytes. While previous studies have reported CD68 as a pan-
macrophage marker, from our study and previous published literature it is clear CD68 
is not a pan-macrophage marker [322,411]. The nature of these cells is unknown as in 
vitro CD68 is expressed on both M1-like and M2-like macrophages [412]. However 
there was a clear correlation of CD68+ macrophages with increased arginase+ and 
iNOS+ cells in the tumour. While the expression of iNOS was restricted to cells with 
a macrophage morphology, arginase expression was present in both macrophages and 
neutrophils. CD68+ recruitment is associated with an increased immunologically 
active microenvironment from an iNOS and arginase perspective. Thus it is 
hypothesized that CD68+ macrophages have an active phenotype. The failure to draw 
consistent prognostic indications from macrophage infiltration in melanoma could be 
due to reduced macrophage activity, whereby the cells have no effect on tumour 
progression, or the prognostic effect is masked by opposing biological effects. Other 
studies have similarly indicated that CD68+ macrophages can be absent in some 
melanomas [247]. 
CD68+ infiltration was also positively associated with BRAF status. These findings 
are significant in the context of BRAF inhibition, in which macrophages have been 
implicated in therapeutic resistance [413]. Similarly, macrophage derived factors such 
as hepatocyte growth factor (HGF) and epidermal growth factor (EGF) have been 
implicated in the resistance to BRAF inhibitors [414,415]. BRAF activity is known to 
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increase glycolysis, and subsequent dependence on glycolysis is a major mechanism 
through which BRAF inhibitors can reduce tumour growth [416,417]. Increased 
lactate levels, which can be expected as a result of overactive glycolysis, can polarize 
macrophages to an M2-like phenotype [405]. M2 polarization of macrophages can 
reactive mitogen-activated protein kinase (MAPK) signalling in tumour cells via 
VEGF secretion [413,335]. While these studies focused on M2-like macrophages, M1-
like macrophages were also shown to mediate resistance of melanoma cells to 
mitogen-activated protein kinase kinase (MEK) inhibition. These results serve as a 
valid hypothesis for macrophages contributing to developed resistance to BRAF 
inhibitors, whereby preventing M2 polarization of TAMs could prolong the duration 
of response to BRAF inhibitors. 
The evaluation of CD68+ macrophage phenotype may very between tumour and tissue 
type. Other studies have shown that CD163+ cells can also express iNOS, indicating 
the existence of non-binary macrophage subsets [418]. Recent advances of RNA 
sequencing technology have been expanded to use on FFPE tissue [419]. Because of 
discrepancies between murine models and human disease and the difficulty of 
performing detailed examination of fresh human tissue it is hoped that single cell RNA 
sequencing which can give more complete phenotypic descriptions on a cellular level 
may reveal a more complete description. Current preclinical targeting of TAMs is 
largely based on presumptions of TAMs adopting an M2 phenotype and contributing 
to tumour progression, supported by prognostic links with intratumoural TAM 
accumulation, in many tumours types. Further interrogation of RNA sequencing data 
will provide a more detailed description of the many discrete physiological roles of 
TAMs.  
It is largely believed that any effective immunotherapeutic, must effectively stimulate 
effective T cell responses or provide a source of effective T cells. As such the role of 
macrophages in immunotherapy has largely been in the context of their ability to 
promote or inhibit T cell responses [267]. Specifically, the current focus in the 
literature is on preventing M2 macrophage polarization of macrophages. Contrary to 
this, our study has shown that it is possible to have M2-like macrophages, which can 
promote T cell responses. Thus our results indicate that macrophage polarization can 




In support of the hypothesis of CD68+ macrophages having a meaningful role in 
tumour biology, the correlations of CD68+ and CD163+ macrophage infiltration in our 
study with total gene expression in the tumour were positive and negative respectively. 
While both peritumoural and intratumoural recruitment of CD68+ cells correlated to 
the regulation of a number of genes, involved in cell death and inflammation, among 
other processes, there was no correlation between CD163+ macrophage recruitment 
and gene expression. These results also undermine the rational of targeting TAM 
inhibition in the TME, as they indicate that TAMs may be functionally inert in the 
TME. Therapeutic strategies should instead focus on preserving or boosting the 
function of CD68+ M1-like macrophages. 
There has been intense interest in the contribution of circulating inflammatory 
monocytes to tumour growth in murine models. In PDAC inhibition of the 
mobilization of inflammatory monocytes from the bone marrow, and consequent the 
reduction of recruitment to the tumour has been associated with positive prognostic 
outcomes in both murine and human disease [149]. Central to this hypothesis is the 
effect of tumour conditioning on monocytes recruited to the TME, in which they 
initially contribute to destructive inflammation, and then become polarized by the 
tumour to support tumour progression [420]. It is currently unclear how the positive 
prognostic outcomes seen in lung cancer and ovarian cancer with increased M1-like 
macrophage density can be aligned with the negative prognostic role of inflammatory 
monocyte infiltration in PDAC [43,56].  
The focus of research on PDAC has led to observations in other murine models, such 
as colorectal cancer, in which the frequency of circulating inflammatory monocytes 
can inversely correlate to survival [329]. 
While the nature of the effect of these cells in the TME is unclear and may vary 
depending on the tumour type, the identification of inflammatory monocytes as a 
prognostic influencer has identified an actionable therapeutic target for cancer 
treatment. It is likely that the role of recruited monocytes in tumour biology depends 
on the specific cancer type and anatomical site. 
In agreement with other murine tumour models, in a murine model of melanoma, we 
observed increased levels of circulating inflammatory monocyte as disease 
progressed.  To determine the role of these cells in the TME, we developed a novel 
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protocol of BMDM generation, optimised for the study of inflammatory monocytes, 
and determined the effect of tumour conditioning on these cells using melanoma, 
B16F10, cell line conditioned medium. 
For in vitro research of monocytes and macrophages there are competing factors in 
determining the protocols used. From one perspective, we must standardize the 
protocols used to increase the repeatability and comparability of the literature [24]. 
However, given the known role of epigenetics in determining the behaviour of 
monocytes and macrophages, it is also essential that we rationally design protocols of 
BMDM generation to accurately reflect in vivo subsets we wish to study [268]. A 
reasonable outcome may be that there will be a central database of a limited number 
of protocols from which researchers select depending on the cell of interest. The 
protocol presented here is rationally robust and future studies comparing BMDM 
protocols to in vivo subsets will continue to question previous protocols. 
Using our model, interestingly, as we had seen a predominant population of inactive 
CD163+ macrophages in human melanoma, conditioned medium had the effect of 
increasing the murine M2-associated surface markers, CD115 and CD206. This 
increase in M2 markers was upregulated in the absence of any major impact on 
functional protein expression such as arginase, iNOS, IL-10 or IL-6. In effect these 
results mirror the clinical hypothesis shown in chapter 3, in which CD68+ 
inflammatory monocytes are recruited to the TME and polarized to an M2 CD163+ 
phenotype.  
Furthermore, analysis of the effect of conditioned BMDMs revealed they retained the 
ability to promote cytotoxic T cell responses, indicating that neutralization of 
inflammatory monocyte recruitment will not induce favourable outcomes in murine 
melanoma. These results are in contrast to other tumour models in which TAMs have 
been shown to skew T cell polarization to a Treg phenotype [421,422,313]. However, 
many studies are based on the hypothesis that BMDMs cultured with M-CSF and IL-
4 with or without IL-13 are representative of TAMs, in lieu of tumour conditioning or 
in combination with tumour conditioning [423]. Many studies exist such as a study 
using human breast cancer cell line conditioned medium on freshly isolated peripheral 
blood monocytes, co-treats with IL-4, IL-10 and M-CSF, in addition to cell line 
conditioned medium before showing conditioned medium can decrease T cell 
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proliferation [313,424,425]. Abbreviated culturing of BMDMs has been shown to be 
representative of inflammatory monocytes and limits the polarizing effect of M-CSF 
[285]. The use of these shortened culturing protocols on other tumour models has not 
yet been evaluated, however the number of studies using shortened protocols is 
increasing, probably reflecting a growing consensus of issues with other longer 
protocols [426-428]. Prolonged exposure to M-CSF may induce an artificial, non-
physiological and irreversible M2 phenotype which masks the effect of tumour 
conditioning. Our results showing an increase of cytotoxic CD8+ T cells and IFNγ 
offer a novel role for ‘M2-like’ TAMs in the TME which could be harnessed to 
increase the rates of tumour rejection. 
Previous efforts to target macrophages in the TME have relied on CSF1R targeting or 
the use of trabectedin, which is a cytotoxic agent selective for macrophages [429]. 
However the range of delivery methods and treatments which can effective harness or 
manipulate macrophage behaviour have increased greatly in recent years. 
Nanoparticles such as liposomes can effectively deliver encapsulated drugs 
specifically to phagocytic macrophages [430]. There are a range of epigenetic 
regulators which can effectively control macrophage polarization [268]. Recent 
advances in clustered regularly interspaced short palindromic repeats (CRISPR) allow 
effective tissue targeting [431]. In this context, the ability of TAMs to promote 
cytotoxic T cell responses is significant, epigenetic regulators which can impair 
glycolysis and the citric acid cycle but maintain an M2 macrophage phenotype may 
offer superior alternatives in comparison to regulators which boost M1 polarization 
[432]. 
ECT is commonly administered clinically with high complete response rates. One 
advantage of treatment is the localized effect of treatment with adjacent exposed 
healthy tissue remaining apparently unaffected [433,434]. Facial nerves, parotid ducts, 
eyelids and tear apparatus have all been exposed to treatment with no observed damage 
and retention of normal function [433].  Treatment can also be performed in proximity 
to vasculature, at distances which may otherwise be considered too closely associated 
for surgical interventions. The safety of nearby tissues may be tissue specific, while 
no serious adverse events have been recorded for the treatment of routine dermal 
lesions, the combination of ECT with subsequent radiotherapy has suggested that ECT 
may be the cause of osteoradionecrosis following treatment of tumours on the floor of 
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the mouth, and reconstructive surgery is common following treatment of tumours 
located in the bucca, floor of mouth, or base of tongue [435].  
While adjacent tissues are commonly unaffected, non-neoplastic cells within the TME 
are exposed to equivalent EP. The TME contains a wide diversity and high 
concentration of stromal cells and immune cells. Preliminary in vitro studies have been 
performed examining the effect of EP on fibroblast and vascular endothelial and non-
vascular endothelial cell lines. Vascular endothelial cells have been shown to be highly 
sensitive to treatment with markedly reduced survival [436,437]. Fibroblast cell lines 
have been shown to be resistant to ECT induced cell death in comparison to tumour 
cells, indicating a cell type specific sensitivities [436,438]. In vitro results have been 
corroborated by in vivo studies which have observed restricted blood flow and 
irreversible damaged of intratumoural vasculature following ECT, a phenomenon 
which has been exploited for the palliative treatment of bleeding melanoma lesions  
[439,440]. 
Investigation of the effect of EP and ECT on intratumoural immune cells has not yet 
been investigated. It is known that ECT can induce an immunogenic form of cell death 
in cancer cells, however, immunogenic cell death is only relevant in the presence of a 
competent immune system [223]. Calcium electroporation results in a rapid form of 
cell death, indicating that it is likely to represent an immunogenic form of cell death 
[441,442]. However, due to the delayed versus acute death seen in ECT versus calcium 
electroporation, it is likely that the supply of PAMPs and damage associated molecular 
patterns (DAMPs) are supplied over different time courses following the respective 
treatments, which could affect the immunogenicity of treatments (Figure 5.5). The 
case report of a systemic anti-cancer response seen in an advanced melanoma patient 
following treatment with ECT and calcium EP, indicates that calcium EP may be 
superior in generating an immunogenic response [225]. 
Activating an immune response following treatment is critical to the development of 
effective, safe and durable cancer treatments. The potential of harnessing this response 
more reliably by optimising therapeutic regimens or by designing combination 
treatments is dependent on understanding the immune response following treatment. 
The focus of the study presented here is to evaluate the effect of treatment on 
macrophages present within the tumour at the time of treatment, as these cells are 
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likely to represent a significant proportion of the immune compartment following 
treatment in addition to the cells which may infiltrate the tumour following treatment 
[380]. Having shown that TAMs can boost cytotoxic CD8+ T cell responses, we next 
examined if delivery of treatment could be optimized to enhance this effect. 
Using a model of melanoma conditioned macrophages, we have shown that 
macrophages are less susceptible to membrane poration than tumour cells when given 
equivalent treatment. While macrophage membranes reseal, there is a significant loss 
of viability following treatment. Promisingly, the ability of surviving macrophages to 
stimulate T cell responses following treatment is not impaired. These results are 
significant in the context of immunogenic cell death shown following ECT [443,223]. 
The efficacy of Ipilimumab in melanoma patients has been shown to be almost 
doubled when combined with local ablative therapies, and there is significant interest 
in the combination of Ipilimumab with ECT, with further clinical evaluation ongoing 
(EU clinical trials number 2014-004420-22) [444,445]. As discussed in section 1.7.8, 
the improved tolerability of Ipilimumab when combined with GM-CSF may indicate 
that beneficial intratumoural macrophage behaviour can improve therapeutic delivery 
[201]. 
ECT is regularly given to advanced melanoma patients in Europe and the US where 
treatment with immunotherapies is offered to all suitable patients. There are no 
powered prospective studies showing a significant effect of ECT on response to 
immunotherapies [382,444]. However there are studies which provide sufficient 
evidence to justify a powered controlled trial [444]. Because of the affordability of 
ECT and absence of a patentable element of treatment, it is unclear who would fund 
such a trial, which would require highly costly immunotherapies. 
Further to the promising clinical observations in response to ECT in combination with 
immunotherapy, there is significant progress being made in the field of electroporation 
to expand treatment opportunities to new organ types, to optimize therapy to enhance 
responses, and to optimise delivery to facilitate pain free delivery. Substitution of 
chemotherapy with calcium, without any loss of efficacy, has been a major 
breakthrough. The use of calcium with high frequency electrical parameters, which 
are also under development, could revolutionize the field of electroporation in which 
theatres and cytotoxic drugs are no longer required. Thus EP could offer an ideal 
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accompaniment to costly immunotherapeutics, which is tolerable, easily administered, 
economical, and can enhance response rates. 
To position EP treatments as a potential co-treatment to immunotherapy, it is 
necessary to comprehensively understand treatment and optimise the immunogenicity 
of treatment. Understanding the effect of treatment on the immune compartment is 
critical to improving treatment. To fully understand the immune response it is 
necessary to establish the effect of treatment on exposed cells, the immune cell 
recruitment following treatment, and the in vivo immune responses following 
treatment. The data presented here is positive, in indicating the effect of calcium 
electroporation on intratumoural macrophages can be immunostimulatory at the 
correct calcium concentration.  
Our understanding of the potential of tissue resident macrophages to self-maintain, 
independent of circulating monocytes has revolutionized our understanding of 
terminal macrophage differentiation [446]. It has recently been established that tissue 
resident macrophages can contribute to TAMs in a murine model of colorectal cancer 
and self-maintain [366]. It is difficult to perform lineage determination in clinical 
disease however circulating monocytes are still considered to be the predominant 
source of TAMs. Analysis of long term effects of bleomycin on BMDMs is not 
possible, as BMDMs have limited replicative potential when grown in vitro [447]. The 
reduction of viability following ECT is in line with the hypothesis that macrophages 
are susceptible to bleomycin induced cell death following treatment, as has been 
previously shown [448]. However the induction of immunological memory following 
ECT in combination with agonistic anti-inducible T-cell costimulatory (ICOS) 
antibodies has previously been shown in murine models, indicating that the immune 
response is intact [381].  
The addition of calcium to EP treatment did not affect the level of membrane poration, 
however it played a protective role in increasing viability at 24hrs and 5 days following 
treatment. Calcium prevented the decrease of the activation markers F4/80 and CD206 
following EP. F4/80 is an epidermal growth factor-transmembrane 7 family protein 
and a G-protein coupled receptor, which can promote the generation Tregs [449]. 
CD206 mediated engagement of tumoural mucins has also been shown to promote a 
suppressive phenotype [450]. However the addition of calcium had no effect on T cell 
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proliferation and did not increase Treg polarization. Furthermore a higher dose of 
calcium resulted in a marked increase if IFNγ levels following coculture indicating the 
promotion of a type 1 cytotoxic T cell response. These results indicate that using a 
dose in the region of 5mM calcium in combination with EP will induce favourable 
immunogenic responses following treatment. 
The lowered arginase activity of treated cells and increased CD8+ T cell proliferation, 
CD8+ T cell cytotoxicity, and IFNγ secretion in response to calcium appears to be 
conducive to the generation of anti-cancer cytotoxic responses, which provides a 
hypothesis to explain the clinical case report of systemic anti-cancer response 
following calcium EP [225]. The beneficial effects of antitumour T cell mediated 
effects have been shown at length and are a positive indicator for the translation of the 
current treatment regimen to in vivo murine models [451]. Due to the local delivery of 
electroporation and tissue contact required, subcutaneous tumour models are 
frequently adopted, and while appropriate for the current study in melanoma there are 
indications this treatment could be effective in other orthotopic tumour models [452]. 
There are a range of local ablative and non-ablative treatments being investigated as 
appropriate combination treatments for immunotherapeutics, however we propose that 
given the results shown here, calcium EP may provide an effective and cost effective 
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1. Genes regulated by intratumoural CD68+ macrophage density represented in 




























3. Genes regulated by BRAF status represented in figure 3.8 
Negatively 
regulated 
Positively 
regulated 
OLIG2 IL1RAP 
ULK1 ABCB5 
WISP1 CKB 
FABP4 FLJ10474 
CCL14 KIF14 
F10 SLC7A5 
ADIPOQ E2F1 
PLA2G2A CDK2 
CHAD SEC22C 
JUN MKI67 
RAMP2 UBE2T 
DLC1 CDKN3 
ANGPT1 ITGA3 
MAGEB1 L1CAM 
ANGPT2 NPC1 
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RTN4RL1  
TEK  
MAML2  
BAIAP3  
PDGFC  
VCAM1  
MMP11  
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